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Chapter - I 
1.1.THYROID GLAND 
                 The thyroid gland is one of the largest endocrine glands. The thyroid gland 
produces two related hormones, Thyroxine(T4) and Triiodothronine (T3). Acting through 
nuclear receptors, these hormones play a critical role in cell differentiation during 
development and help maintain thermogenic and metabolic homeostasis in the adult. 
                  The thyroid gland is a butterfly-shaped organ and is composed of two cone-like 
lobes or wings, lobus dexter (right lobe) and lobus sinister (left lobe). The two lobes are 
connected by an isthumus located inferior to the cricoid cartilage. 
                 The organ is situated on the anterior side of the neck, lying against and around 
the larynx and trachea, reaching posterior to the oesophagus and carotid sheath. It starts 
cranially at the oblique line on the thyroid cartilage (just below the laryngeal prominence, or 
'Adam's Apple'), and extends inferiorly to approximately the fifth or sixth tracheal ring. It is a 
highly vascular gland that weighs about 12 to 20g and is surrounded by a fibrous capsule. 
The lobes are roughly cone-shaped, about 5 cm long and 3 cm wide. Four parathyroid glands 
producing parathyroid hormone are located in the posterior region of each lobe of thyroid.(1, 2) 
 
 
Fig NO 1:       GROSS ANATOMY OF THE THYROID GLAND            
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                The arterial blood supply to the gland is through the superior and inferior thyroid 
arteries. The superior thyroid artery is a branch of the external carotid artery and the inferior 
thyroid artery is a branch of the subclavian artery. The venous return is by the thyroid veins 
which drain into the internal jugular veins. 
                 The thyroid hormone synthesis normally begins at about 11 week’s gestation. The 
thyroid gland development is controlled by a series of developmental transcription factors 
like thyroid transcription factor 1(TTF1), thyroid transcription factor 1(TTF2) and paired 
homeobox-8(PAX-8). In combination, they orchestrate thyroid cell development and 
induction of thyroid-specific genes such as thyroglobulin (Tg), thyroid peroxidise (TPO), the 
sodium iodide symporter (NIS) and the thyroid-stimulating hormone receptor (TSH-R). 
                 The thyroid gland is composed of large numbers of closed follicles (100 to 300 
micrometers in diameter) filled with a secretory substance called colloid and lined with 
cuboidal epithelial cells that secrete into the interior of the follicles. The major constituent of 
colloid is the large glycoprotein thyroglobulin, which contains the thyroid hormones within 
its molecule. 
                 Once the secretion has entered the follicles, it must be absorbed back through the 
follicular epithelium into the blood before it can function in the body. The thyroid follicular 
cells are polarized –the basolateral surface is apposed to the blood stream and an apical 
surface faces the follicular lumen. . Between the follicles there are other cells found singly or 
in small groups: parafollicular cells, also called C-cells, which secrete the hormone calcitonin 
an important hormone for calcium metabolism.(3-5) 
 
 
FIG NO: 2 MICROSCOPIC STRUCTURE OF THE THYROID GLAND 
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1.2.THYROID HORMONE 
                 The thyroid hormones, triiodothyronine (T3) and thyroxine (T4) are tyrosine based 
hormones produced by thyroid gland that are primarily responsible for the regulation of 
metabolism. 
                 The thyroid hormones T3 and T4 are formed in a large prohormone molecule-
thyroglobulin, the major component of the thyroid gland. Thyroglobulin is synthesized by the 
endoplasmic reticulum and golgi apparatus in the thyroid follicular cells and secreted into the 
lumen of the follicles. It is a large glycoprotein (660,000 daltons) made up of two identical 
subunits, each with a molecular weight of 330,000 daltons. It is of special importance 
because it is necessary for the synthesis of thyroid hormones and represents their form of 
storage. 
                  Each molecule of thyroglobulin contains about 70 tyrosine amino acids, and they 
are the major substrates that combine with iodine to form the thyroid hormones. The 
thyroxine and triiodothyronine hormones formed from the tyrosine amino acids remains as a 
part of the thyroglobulin molecule during synthesis of the thyroid hormones and even 
afterward as stored hormones in the follicular colloid. 
                 About 93 per cent of the metabolically active hormone secreted by the thyroid 
gland is thyroxine and 7 percent triiodothyronine. (6, 7) 
 
 
THYROXINE 
 
 
3, 5, 3′-TRIIODOTHYRONINE 
THYROID HORMONE STRUCTURE 
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 1.3. REGULATION OF THYROID HORMONE PRODUCTION 
                 The production of thyroid hormones is regulated by the hypothalamic-pituitary 
thyroid axis. Thyrotropin-releasing hormone (TRH) is synthesized in the hypothalamus and 
stimulates the release of thyroid-stimulating hormone (TSH) from the anterior pituitary. 
Secretion of TRH is stimulated by exercise, stress, malnutrition, low plasma glucose and 
sleep. 
                 TSH is regulated by the negative feedback of the thyroid hormones; thyroxine (T4) 
and triiodothyronine (T3) acting on the pituitary gland and probably the hypothalamus i.e. 
increased levels of T3 and T4 decrease TSH secretion and vice versa. TSH binds to TSH-
receptor (TSH-R) on the thyroid cell membrane, a GPCR which stimulates the Gs-adenylyl 
cyclase-cyclic AMP pathway. Thus stimulation of the receptor results in increased cAMP 
formation which mediates increase in uptake and transport of iodide, iodination of 
thyroglobulin, and synthesis of iodotyrosines. TSH binding to TSH-R also stimulates 
phospholipase C leading to thyroid cell hypertrophy. Chronic TSH stimulation causes entire 
gland to hypertrophy causing a goiter in the case of iodine deficiency.( 8-10) 
 
1.4. BIO SYNTHESIS OF THYROID HORMONES 
                 The formation of the thyroid hormones depends on an exogenous supply of iodide. 
The thyroid gland is unique in that it is the only tissue of the body able to accumulate iodine 
in large quantities and incorporate it into hormones. 
 
Iodine-Essential for Thyroid Hormone Synthesis 
• Iodine is an essential raw material for thyroid hormone synthesis. 
• The minimum daily iodine intake that will maintain normal thyroid function is 150µg. 
• Average dietary intake is approximately 500µg/day. 
• About 120µg/day enter the thyroid.  
• The thyroid secretes 80µ/day in the form of T3 and T4. 
• 40µg/day diffuses back into the extracellular fluid (ECF). 
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The major steps in the synthesis, storage, release and inter-conversion of thyroid hormones 
are: 
 ACTIVE UPTAKE OF IODIDE BY THE FOLLICULAR CELLS 
• The first stage in the formation of thyroid hormones is transport of iodides from the 
blood into the thyroid glandular cells and follicles. 
• The basal membrane of the thyroid cell has the specific ability to pump the iodide 
actively to the interior of the cell. This is called iodide trapping. 
• The Basolateral membrane of thyroid cell possesses a pump called Na+/I- 
symporter(NIS), which  transports two Na+ ions and one I- ion into the cell with each 
cycle, against the electrochemical gradient for I-.(11-13) 
 
 
 OXIDATION AND IODINATION 
• The oxidation of iodide to its active form of iodine and the iodination of tyrosine are 
catalyzed by thyroid peroxidase, a heme-containing glycoprotein bound to the apical 
membrane of thyroid cells that utilizes hydrogen peroxide (H2O2) as the oxidant. 
• This iodine is then capable of combining directly with the amino acid tyrosine 
residues on the thyroglobulin (organification) 
• This process occurs at the apical membrane of thyrocytes, facing the colloid. 
• Tyrosine is first iodized to monoiodotyrosine and then to diiodotyrosine.(14-20) 
 
 
 COUPLING REACTION 
• The final step in the process of hormone synthesis is the coupling of two appropriate 
iodotyrosine residues, giving an iodothyronine residue  
• T4 is formed by condensation of two molecules of DIT. 
• T3 is formed by condensation of MIT with DIT. 
• The reaction is catalyzed by thyroid peroxidase (TPO) and requires H2O2 which is the 
co-factor for TPO.(21,22) 
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 STORAGE OF THYROID HORMONES 
 
• The thyroid gland is unusual among the endocrine glands in its ability to store large 
amounts of hormone. 
• Each thyroglobulin molecule contains up to 30 thyroxine molecules and a few 
triiodothyronine molecules.  
• Stored Thyroid Hormones maintain the body’s requirement of T3 and T4 for up to 2-3 
months. 
 
 
 RELEASE OF THYROID HORMONES 
 
• Thyroglobulin is secreted into the circulation by Proteolysis. 
• Thyroglobulin appears as intracellular colloid droplets (endocytosis) which apparently 
fuse with lysosomes containing the requisite proteolytic enzymes. 
• Protease enzymes digest the thyroglobulin molecules and release T3 and T4 and 
diffuse through the base of the thyroid cell into the blood. 
• About 93 per cent of the thyroid hormone released from the thyroid gland is normally 
thyroxine; only 7 per cent is triiodothyronine.  
 
 
 PERIPHERAL CONVERSION OF T4 TO T3   
 
• Mono-deiodination of T4 in peripheral tissues accounts for about 80% of circulating 
T3.  
• The major nonthyroidal site of conversion of T4 to T3 is the liver 
• Removal of the 5′-or outer ring iodine leads to the formation of T3 in the “activating” 
metabolic pathway. 
• The type I 5′-deiodinase (D1) is expressed in the liver, kidney and thyroid; generates 
circulating T3 that is used by most peripheral target tissues. 
• Type II 5′-deiodinase (D2) is expressed in the brain, pituitary, skeletal and cardiac 
muscle; supplies intracellular T3 to these tissues.(23,24) 
 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 7 
 
 TRANSPORT 
 
• The released hormones in the circulation bind to albumin, thyroid-binding prealbumin 
(TBPA) and thyroid-binding globulin (TBG). 
• The TBG has a high affinity for T3 and lower affinity for T3.  
• The unbound T4 and T3 are the biologically active forms of the hormones.  
• Thyroid hormones are taken into cells by facilitated diffusion or by active transport 
secondary to a sodium gradient. 
• A great part of T4 is stored in liver and kidney, whereas most T3 appears in muscle 
and brain. 
 
 DEGRADATION AND EXCRETION 
 
• Degradative metabolism of the thyroid hormones occurs mainly in the liver, where 
both T3 and T4 are conjugated to form either glucuronide (mainly T4) or sulfate 
(mainly T3) through the phenolic hydroxyl group. 
• The resulting iodothyronine conjugates are excreted via the bile into the intestine. 
• It also undergoes marginal enterohepatic circulation and is excreted unconjugated in 
faeces.(25) 
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FIG NO 3:  BIOSYNTHESIS OF THYROID HORMONE 
 
 
 CHEMISTRY OF T3 AND T4 
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1.5. THYROID HORMONE RECEPTOR 
 
                 The thyroid hormone receptor (TR) is a type of nuclear receptor. Thyroid 
hormones act by binding to nuclear thyroid hormone receptors (TRs) α and β. Both the 
receptors are variably spliced to form unique isoforms. There are three isoforms of 
the thyroid hormone receptor designated as α-1, β-1 and β-2 that are able to bind thyroid 
hormone. The relative levels of expression of the isoforms among the organs are  
 
• TR-α1 –expressed in cardiac and skeletal muscles 
• TR-β1 -expressed in brain, liver and kidney 
• TR-β2 -expression primarily limited to the hypothalamus and pituitary 
 
The thyroid receptor contains a central DNA-binding domain and a C-terminal ligand binding 
domain. They bind to specific DNA sequences named Thyroid Response Elements (TREs), in 
the promoter region of the target genes. The receptor binds as homodimer or as heterodimers 
with retinoic acid X receptors (RXRs). The activated receptor can either stimulate gene 
transcription or inhibit transcription depending on the nature of regulatory elements in the 
target genes. 
Binding of thyroid hormone, results in a conformational change in TR which displaces co-
repressor from the receptor/DNA complex and allows the recruitment of co-
activator proteins. The DNA/TR/co-activator complex thus enhances transcription by 
recruiting RNA polymerase that transcribes downstream DNA into messenger RNA and 
eventually new proteins are synthesized, that results in a change in cell function. . In the 
absence of hormone, TR binds with co-repressor proteins that inhibit gene transcription.( 26, 27) 
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FIG NO 4: THYROID HORMONE RECEPTOR:   
 
             T4 and T3 readily diffuse through the cell membrane. Much of the T4 is deiodinated to        
form    T3, which interacts with the thyroid hormone receptor, bound as a heterodimer with a 
retinoid X receptor, of the thyroid hormone response element of the gene. This causes either 
increases or decreases in transcription of genes that lead to formation of proteins, thus 
producing the thyroid hormone response of the cell. The actions of thyroid hormone on cells 
of several different systems are shown. 
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1.6. PHYSIOLOGIC FUNCTIONS OF THE THYROID HORMONES 
               
                The general effect of thyroid hormone is to activate nuclear transcription of large 
numbers of genes. Therefore, in virtually all cells of the body, great numbers of protein 
enzymes, structural proteins, transport proteins, and other substances are synthesized. The net 
result is generalized increase in functional activity throughout the body.(28) 
 
Effect on Carbohydrate Metabolism 
 Stimulates almost all aspects of carbohydrate metabolism 
 Stimulates uptake of glucose by the cells 
 Stimulates glycolysis and gluconeogenesis 
 Stimulates  rate of absorption from GIT 
 
Effect on Fat Metabolism 
 Fat metabolism is enhanced under the influence of thyroid hormone 
 Decreases concentration of cholesterol, phospholipids, and triglycerides in plasma 
 Increases free fatty acid concentration in the plasma and accelerate the oxidation of 
free fatty acids by cells.(29) 
 
Effect on Basal Metabolic Rate 
 Increases BMR 
 The basal metabolic rate (BMR) can increase to 60 to 100 per cent above normal 
 The rate of protein synthesis is increased, at the same time rate of protein catabolism 
is also increased 
 
Effect on Body Weight 
 Decreases the body weight 
 
Effect on Growth  
 Promotes  growth and development of brain during foetal life 
 Induces growth of bones 
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Effect on the Cardiovascular System 
 Normalize mean arterial blood pressure 
 Increases blood flow and cardiac Output 
 Increases heart rate(30) 
 
Effect on Respiration 
 Increase rate and depth of respiration 
 
Effect on GIT 
 Stimulates secretion of digestive juices 
 Stimulates motility of the gastrointestinal tract 
 Stimulates appetite(31) 
 
Effect on Muscles 
 Stimulates muscles and react with vigor 
 When the quantity of hormone becomes excessive, muscles become weakened 
because of excess protein catabolism  
 
Effect on Sexual Function  
 For normal sexual function, thyroid secretion needs to be approximately normal. 
 In men, lack of thyroid hormone is likely to cause loss of libido; great excesses of the 
hormone, sometimes cause impotence 
 In women, lack of thyroid hormone often causes menorrhagia and polymenorrhea and 
excess of hormone causes oligomenorrhea.(32) 
 
Effect on Other Endocrine Gland 
 Increases secretion of most other endocrine glands 
 Increases secretion of insulin due to excessive glucose metabolism 
 Increases secretion of parathyroid hormone 
 Increases glucocorticoid secretion from adrenal gland(33) 
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1.7. DISORDERS OF THE THYROID 
 
                 Thyroid diseases are very common types of endocrine disorder, particularly in 
middle aged and elderly women. 
 
The types of disorders which are associated with the abnormal secretion of thyroid 
hormones are 
• Hyperthyroidism: a condition where there is an increase in production of thyroid 
hormones due to excessive thyroid function.(34)  
• Hypothyroidism: a condition where there is a decrease in production of thyroid 
hormones due to impaired thyroid function. (35) 
 
 
 
Table No: 1   DISORDERS OF THE THYROID 
 
 
 
 
Hormones Normal Range Interpretation 
TT4 
64-142mmol/L 
 
>142mmol/L indicates 
hyperthyroidism and <64 mmol/L 
indicates hypothyroidism 
TT3 1.46-2.92mmol/L >2.92mmol/L indicates 
hyperthyroidism and <1.46 indicates  
hypothyroidism 
FT4 12-26pmol/L >26pmol/L indicates 
hyperthyroidism  and < 12 pmol/L 
indicates  hypothyroidism 
FT3 0.22-6.78pmol/L >6.78 pmol/L indicates 
hyperthyroidism  and < 0.22  
pmol/L indicates  hypothyroidism 
TSH 0.4-4.8mIU/L <0.4 mIU/L indicates 
hyperthyroidism and >0.4 mIU/L  
indiactes hypothyroidism 
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1.8. HYPERTHYROIDISM 
 
                 Hyperthyroidism, often referred to as an 'overactive thyroid', is a condition in 
which the thyroid gland produces and secretes excessive amounts of the free thyroid 
hormones:  triiodothyronine (T3) and/or thyroxine (T4). 
Thyrotoxicosis is defined as the state of elevated serum levels of T4 (>142mmol/L) and/or T3 
(>2.92mmol/L) which is caused due to hyperthyroidism.(36) 
 
1.9. EPIDEMIOLOGY 
                 The most common cause of hyperthyroidism in the western world is Graves’ 
disease, which accounts for 90% of cases. This form of hyperthyroidism may affect any age 
group, but it is uncommon in childhood and most frequent in the third to fifth decades. 
Women are affected about 10 times more than men. In the UK the prevalence of overt 
hyperthyroidism is 20 per 1000 females and 2 per 1000 males.(37) 
               According to British medical bulletin, the incidence data available for overt 
hyperthyroidism in men and women from large population studies are comparable, at 0.4 per 
1000 women and 0.1 per 1000 men, but the age-specific incidence varies considerably. The 
peak age-specific incidence of Graves' disease was between 20 and 49 years in two studies, 
but increased with age in Iceland and peaked at 60–69 years in Sweden. The peak age-
specific incidence of hyperthyroidism caused by toxic nodular goiter and autonomously 
functioning thyroid adenomas in the Sweden study was >80 years. The only available data in 
a black population, from Johannesburg, South Africa, also suggest a 10-fold lower annual 
incidence of hyperthyroidism (0.09 per 1000 women and 0.007 per 1000 men) than in 
whites.(38) 
                The incidence of hyperthyroidism from toxic multi nodular goiters (TMG) ranges 
from 9% to 16% per 100,000 has been reported. This is the most common cause of new-onset 
hyperthyroidism in adults in the fifth or sixth decade of life. Single toxic adenomas are less 
common; an incidence of 12.6% was noted in the United States, and a higher incidence of 9% 
was noted in Europe. Post partum thyroiditis develops in 4% to 8% of women after delivery 
and in as many as 25% of women with insulin-dependent diabetes.  
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                 The prevalence of hyperthyroidism has been studied in several studies. In an 
epidemiological study from Cochin, subclinical and overt hyperthyroidism were present in 
1.6% and 1.3% of subjects participating in a community survey. In a hospital-based study of 
women from Pondicherry, subclinical and overt hyperthyroidisms were present in 0.6% and 
1.2% of subjects.  More than a third of community-detected hyperthyroid cases have positive 
anti-TPO antibodies, and about 39% of these subjects have a goiter. 
                 Population studies have suggested that about 16.7% of adult subjects have anti-
thyroid peroxidase (TPO) antibodies and about 12.1% have anti-thyroglobulin (TG) 
antibodies. In this same study of 971 subjects, when subjects with abnormal thyroid function 
were excluded, the prevalence of anti-TPO and anti-TG antibodies was 9.5% and 8.5%. 
               The Indian Council of Medical Research established the National Cancer Registry 
Program, and the NCRP has collected the data of more than 3, 00,000 cancer patients 
between the periods 1984 and 1993. Among these patients, the NCRP noted 5614 cases of 
thyroid cancer, and this included 3617 females and 2007 males. The six centers involved in 
the studies were at Mumbai, Delhi, Thiruvananthapuram, Dibrugarh, Chandigarh, and 
Chennai. Among them, Thiruvananthapuram had the highest relative frequency of cases of 
thyroid cancer among all cancer cases enrolled in the hospital registry, 1.99% among males 
and 5.71% among females. The nationwide relative frequency of thyroid cancer among all 
the cancer cases was 0.1%–0.2%. The age-adjusted incidence rates of thyroid cancer per 
100,000 are about 1 for males and 1.8 for females as per the Mumbai Cancer Registry, which 
covered a population of 9.81 million subjects. (39) 
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1.10. AETIOLOGY 
 
                 The most common cause of this syndrome is Grave’s disease, followed by toxic 
multinodular goitre and hyperfunctioning solitary nodules. Autoimmune postpartum and 
subacute thyroiditis, tumors that secrete thyrotropin and drug–induced thyroid dysfunction 
are other important causes.(40) 
 
1. Grave’s disease:  
                 This is the most common cause of hyperthyroidism and is an autoimmune disorder.  
In this disease, the patient produces auto-reactive IgG antibodies that have an antigen 
binding-site, which is complementary to the TSH-receptor found on the cell surface 
membrane of thyroid follicle cells. These IgG antibodies are called thyroid stimulating 
immunoglobulin (TSI) and bind to TSH- receptor. The TSI are synthesized in the thyroid 
gland, bone marrow and lymph nodes. These antibodies hyper-stimulates the receptor and 
consequently triggers follicle cell hypertrophy (toxic goitre), and causes excessive TH 
synthesis/secretion (thyotoxicosis).(41)  
 
A combination of genetic factors including HLA-DR and CTLA-4 polymorphisms 
and environmental factors contribute to the development of TSI.(42) 
 
2. Toxic multinodular goiter: (TMG)  
                  TMG is a condition that affects elderly females who previously had normal 
thyroid function. It is the second most common cause of hyperthyroidism after Grave’s 
disease. This type of hyperthyroidism is common in areas of the world with iodine deficiency 
In TMG the thyroid gland contains many overactive nodules that secrete excessive TH, 
independently to the influence of TSH. (43) 
 
                 TMG usually starts as a non-toxic multinodular goitre, which is formed via the 
hyperplastic response of the thyroid gland to iodine deficiency. Over the time, the non-toxic 
goitre becomes functional and begins to secrete TH hormone.(44) 
 
It is not clearly known why the non-toxic multinodular goitre becomes TMG and 
one theory suggests that the somatic mutations of TSH- receptors found on the cells of the 
nodules causes the autonomous secretion of TH.(45) 
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3. HYPERFUNCTIONING SOLITARY NODULES: 
                 A solitary, autonomously hyperfunctioning thyroid nodule is referred to as 
toxic adenoma. It’s also called as plummers disease. Thyroid adenoma is a benign 
tumour of the thyroid gland, which has originated via somatic mutations of the 
thyrotropin, or thyroid-stimulating hormone (TSH) receptor.The nodule is usually 3 to 
5cm diameter and is not under TSH regulation. This nodule can produce normal or supra-
physiologic amounts of thyroid hormone causing suppression of existing normal thyroid 
tissue.(46) 
 
                 In over 85% of cases, the tumour is silent and the patient is euthyroid. However, in 
about 10% of patients, the adenoma is functional and secretes excessive TH which results in 
symptomatic hyperthyroidism. When functional, the condition is known as toxic thyroid 
adenoma.(47) 
 
4. THYROIDITIS: 
                 Thyroiditis refers to the inflammatory condition of the thyroid gland. Results of 
several investigations have shown that thyroiditis, whether autoimmune, infectious or toxic  
affects apoptotic pathways leading to thyroid follicular cell death. This apoptosis leads to 
follicular disruption and release of hormonal stores into the circulation, resulting in 
hyperthyroidism. After the inflammatory process subsides, mild to moderate hypothyroidism 
generally follows, before complete recovery.(48) 
 
                 Thyroiditis does not cause the thyroid to produce excess hormone. Instead, it 
causes stored thyroid hormone to leak out of the inflamed gland and raise hormone levels in 
the blood.(49) 
 
Thyroiditis is classified into 
 
a) Acute Thyroiditis: 
                 Acute thyroiditis is very rare and is caused mainly due to bacterial and fungal 
infections of the thyroid. 
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b) Subacute Thyroiditis: (Quervain’s Thyroiditis/Granulomatous Thyroiditis/Viral 
Thyroiditis) 
                 This condition involves painful inflammation and enlargement of the thyroid 
gland. This is caused mainly due to viral infections. The condition usually goes away on its 
own in a few months. Many people with subacute thyroiditis briefly develop hypothyroidism 
before the thyroid gland is completely healed. 
 
c) Silent Thyroiditis: 
                 This type of thyroiditis is called “silent” because it is painless and occurs in 
patients with underlying autoimmune thyroid disease. It’s also called post partum thyroiditis 
since condition occurs in up to 5% of women 3 to 6 months after pregnancy.  
Hyperthyroidism in this condition usually lasts for approximately 1 to 2 months. As with 
subacute thyroiditis, women with postpartum thyroiditis often develop hypothyroidism before 
the thyroid gland is completely healed. In some women, the gland does not heal and hormone 
levels remain low. These women must take thyroid hormone replacement for the rest of their 
lives. 
 
5. Drug-Induced Hyperthyroidism: 
                  Drug induced hyperthyroidism is mainly caused in abnormal thyroid gland 
that have lost the protective Wolff-Chaikoff block. There are 2 main drugs that cause 
hyperthyroidism in normal patients:  
 
• Amiodarone:  This is an antiarrhythmic drug. The structure of amiodarone is similar 
to TH, and it can therefore bind to the TH-receptors that are found intra-cellularly in 
many organs, thus inducing hyperthyroid symptoms.  
 
• Exogenous iodine ((Jod-Basedow Phenomenon): Iodine-induced thyrotoxicosis is seen 
commonly in residents of iodine-deficient areas who became hyperthyroid after taking 
excessive iodine supplements, or by eating lots of iodine-rich food. 
 
6. Thyrotoxicosis Factitia: 
                      This is a very uncommon type of hyperthyroidism that is caused by the excessive 
ingestion of exogenous TH. This may be due to an accidental thyroxine overdose in patients 
with hypothyroidism. 
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7. hCG-Induced Hyperthyroidism  
                  Human chorionic gonadotrophin (hCG) is a hormone that is usually secreted by an 
embryo in pregnancy. In pregnancy, its main function is the maintenance of the corpus 
luteum in the ovary, thereby maintaining high progesterone levels that are necessary for a 
normal pregnancy.  
 
                 The structure of hCG is very similar to that of TSH and hCG binds to the TSH 
receptors on the thyroid follicle cells; stimulating the secretion of TH. Hence, excessive hCG 
levels cause hyper-secretion of TH, and subsequent hyperthyroidism.  
 
There are two main conditions that raise plasma hCG concentrations and thus 
cause hyperthyroidism: 
• Pregnancy: hCG is raised physiologically in pregnancy, and this can cause a 
transient, pregnancy-induced hyperthyroidism.  
• Tumours: Some tumours secrete large quantities of hCG, and this can cause 
hyperthyroidism. 
 
8. Thyroid Cancer 
                     Thyroid carcinoma is the most common malignancy of the endocrine system. 
Most malignant tumours of the thyroid gland secrete excessive TH and can thus cause 
hyperthyroidism. There are two types of thyroid gland carcinoma that cause excess TH 
secretion:  
 
• Follicular thyroid cancer (FTC): This is a primary tumour of the thyroid gland, 
which originates from the follicle cells. 
• Metastatic differentiated thyroid carcinoma: This is a highly differentiated thyroid 
gland malignancy that has metastasised from another site in the body (the main 
primary tumours that metastasise to the thyroid are from the kidneys, lungs, breast, 
oesophagus or uterus).  
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TABLE NO: 1.1 
 
 
 
 
  
 
CAUSES PATHOPHYSIOLOGY 
 
PRIMARY HYPERTHYROIDISM 
 
• Graves Disease 
 
• TMN Goitre 
 
• Toxic adenoma 
 
• Struma Ovarii 
      
• Jod-Basedow 
 
• Sub-Acute Thyroiditis 
 
• Silent Thyroiditis 
 
• Thyrotoxicosis Factitia 
 
 
 
SECONDARY HYPERTHYROIDISM 
 
• hCG Induced Thyrotoxicosis 
 
 
 
 
 
Increased glandular stimulation 
 
Autonomous hormone production 
 
Autonomous hormone production 
 
Extra glandular production 
 
Increased glandular stimulation 
 
Leakage of hormone from the gland 
 
Leakage of hormone from the gland 
 
Exogenous hormone intake 
 
 
 
 
 
Increased glandular secretion 
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1.11. PATHOPHYSIOLOGY 
 
 
                                                            PATHOPHYSILOGY(50) 
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1.12. SIGNS AND SYMPTOMS 
                 The clinical manifestations of hyperthyroidism are directly related to increased TH 
secretion. The majority of the signs and symptoms are just exaggerated forms of the normal 
effect of TH, and these include: (51,52) 
TABLE NO:2 
 
Skin and Appendages 
 
 
Warm and moist skin, Thinning or loss of hair, 
Exophthalmos (protrusion of the eyeball), Lid 
retraction, Lid lag, Increased sweating, Heat 
intolerance, Ophthalmoplegia, Plummers nail, 
Palmar erthyma, Peritibial myxodema 
 
 
Nervous system 
 
 
Insomnia, Irritability, Nervousness, Anxiety, 
Psychosis (rarely), Choreoathetosis, Hyperkinesis 
(children) 
 
 
Musculoskeletal 
 
 
Osteoporosis, Muscle weakness, Tremor, Rapid 
Deep tendon reflexes, Fatigue 
 
 
Gastro intestinal 
 
 
Weight loss with increased appetite, Diarrhoea 
 
Cardio vascular 
 
 
Palpitations, Tachycardia, Angina , Atrial 
fibrillation 
 
Genito urinary 
 
Amenorrhoea 
 
Neck 
 
Goitre 
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1.13. DIAGNOSIS OF HYPER THYROIDISM 
 
                 Several laboratory tests are available to assess thyroid homeostasis and metabolic 
function.  These tests evaluate circulating hormone levels, glandular activity, hypothalamic – 
pituitary function, autoimmunity and various non-specific metabolic indices. 
 
 Circulating Hormone Levels 
Total T3: 
• Total T3 tests are often useful to diagnosis hyperthyroidism or to determine the 
severity of the hyperthyroidism.  
• Serum concentration of total T3 is measured by radioimmunoassay method. 
• Hyper thyroid patients have T3 >2.92 mmol/L 
 
Total T4: 
• Serum total T4 concentration is measured by radioimmunoassay.  
• This test measures the total t4 in blood i.e.; both the bound and free form of the 
hormone.  
• Hyper thyroid patients have T4 > 142mmol/L 
 
              Several laboratories measure the total T4 and total T3 which is not a true reflection 
of the thyroid status of an individual. This is because thyroid hormones circulate in the body 
largely in the inactive form, bound to carrier proteins (thyroid binding globulin (TBG), 
transthyretin and albumin) while only the small unbound fraction is metabolically active. The 
development of newer immunoassay methods for determining free T3 and T4 has overcome 
many of these problems.(53) 
 
Free Thyroxin (FT4): 
• The free thyroxin can be measured by equilibrium dialysis or by analog type radio 
immune assays.  
• It’s a direct method of measurement.  
• By employing this technique, TBG's variable effect on total T4 concentration is 
eliminated, thereby affording more precise estimates of thyroid status.  
• Hyper thyroid patients have FT4 >12-26pmol/L.(54) 
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Free Triiodothyronine (FT3): 
• The free thyroxin can be measured by immunoenzymatic assay.  
• It’s a direct method of measurement.  
• The concentration of FT3 increases in the case of hyper thyroidism.  
• Hyper thyroid patients have FT3 > 0.22-6.78 pmol/L 
 
 Glandular Activity 
Radio Active Iodine Uptake (RAIU) and Thyroid Scanning: 
                 RAIU measures only the iodine trapping ability of the gland without regard to the 
iodine’s ultimate rate. After the tracer dose of radioactive iodine, the percentage of iodine 
uptake is measured at 5 and at 24 hours. An elevated update of >35% at 24 hours occurs in 
hyperthyroidism. The most commonly used isotopes of iodine are iodine 123 I,125 I,131 I 
and the thyroid gland uptake these isotopes. After the uptake nuclear imaging of the patient is 
done.  
• Grave’s disease is characterized by an enlarged gland and increased tracer uptake that 
is distributed homogeneously. 
• Toxic adenomas appear as focal areas of increased uptake, with suppressed tracer 
uptake in the remainder of the gland. 
• Sub acute thyroiditis is associated with very low update because of follicular damage 
and TSH suppression 
• In toxic multi nodular Goiter, there are multiple areas of relatively increased or 
decreased trace update.  
                A thyroid scan is usually done after RAIU or 99mTc pertechnetate uptake . This 
detects hypo functioning, non-iodine –concentrating, hyper functioning, hyper-iodine –
concentrating areas in parts of or the whole gland .  The thyroid scan shows how the iodine is 
distributed in the gland.(55) 
 
 Hypothalamic – Pituitary Function 
                 The integrity of the negative feed-back hypothalamic pituitary axis is evaluated by 
the serum thyrotropin (TSH) and the thyrotropin – releasing hormone test (TRH). The TRH is 
mainly used for diagonosing hypothyroidism. 
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TSH or Thyrotropin Test: 
                 A low TSH level in the blood is the most accurate indicator of hyper thyroidism.   
The body shuts off production of this pituitary hormone when the thyroid gland even slightly 
overproduces thyroid hormone. If the TSH level is low, it is very important to check the 
thyroid hormone levels to confirm the diagnosis of the hyper thyroidism. Recently, a new 
immunoassay methodology has been applied to the measurement of TSH. Depending on the 
type of label attached to the TSH antibody, the assay is variously called the 
immunoradiometric assay, the immunofluorimetric assay, the immunochemiluminometric 
assay, or the immunoenzymometric assay. 
Hyperthyroid patients have TSH valus < 0.4mIU/L(56) 
 
 Test of Auto Immunity: Antibodies 
Antithyroglobulin (ATgA) and Anti Microsomal Antibodies (AMA): 
                 The two main antigens are identified in the thyroid gland are 
antithyroglobulin(ATgA) and anti-microsomal antibodies (AMA). The presence of these 
antibodies suggests an auto immune process such as Graves’s disease and /or Hashimotos 
thyroiditis.  The levels of ATgA are higher during the acute phase of auto immune thyroid 
disease and decline during remission and after therapy.  The AMA is the more sensitive of 
the two antibodies because levels remain detectable after remission where as ATgA titres 
revert to normal.(57) 
 
Thyroid Receptor Antibody (TRab) 
                 An IgG immunoglobulin capable of stimulating the thyroid gland like TSH, is 
commonly present in 90% of patients with Grave’s disease. The TRab will help to confirm 
the diagnosis of Grave’s diseases in clinically euthyroid patients with an atypical 
presentation. A high maternal TRab level in pregnant female provides predictive information 
about the risk of neonatal Grave’s disease.(58) 
 
 Non-Specific Indices 
                  Serum cholesterol, SGOT, Creatine, phosphokinase (CPK), and LDH levels are 
decresed in severe hyper thyroidism. (59) 
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1.14. DIAGONOSIS 
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  1.15. TREATMENT 
 
                 Hyperthyroidism may be treated pharmacologically or surgically. In general, 
surgery is used only when there are problems resulting from compression of the trachea, and 
it is usual to remove only part of the organ. Although the condition of hyperthyroidism can be 
controlled with antithyroid drugs, these drugs do not alter the underlying autoimmune 
mechanisms or improve the exophthalmos associated with Graves' disease. 
                 A large number of compounds are capable of interfering, directly or indirectly, 
with the synthesis, release, or action of thyroid hormones. The major inhibitors are listed in 
table no:3 
TABLE NO: 2.1 
 
DRUGS USED FOR THE TREATMENT OF HYPERTHYROIDISM 
 
1. Anti Thyroid drugs                                      Propyl-thiouracil, Methimazol, Carbimazole 
2. Ionic Inhibitors                                            Potassium perchlorate, Thiocyanate 
3. Iodine and Iodine-Containing                     Sodium Iodide, Potassium Iodide, Lugols           
Agents                                                         Iodine, Oral Cholecystographic Agents 
 
4. Radiation Therapy                                      Radioactive Iodine (Iodotope I-131) 
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1. Anti Thyroid Drugs:                                                                                                                  
They interfere directly with the synthesis of thyroid hormones. These drugs bind to and 
inhibit the thyroperoxidase; they thus block thyroid hormone synthesis by inhibiting:- 
• Coupling of iodotyrosines 
• Formation of MIT 
• Conversion of MIT TO DIT 
 
2. Ionic Inhibitors: 
                 They act by blocking the iodide transport mechanism. These drugs are 
competitive inhibitor of thyroidal I- transport via the Sodium Iodide Symporter (NIS). Thus 
they competitively inhibit trapping of iodide by the thyroid gland. 
 
3. Iodine And Iodine-Containing Agents:  
                  When administered in pharmacological amounts, iodides causes a transient 
inhibition of the uptake and incorporation of I- into Tg . In addition, high doses of KI also 
inhibit the secretion of thyroid hormone and thyroid blood flow. These effects make KI an 
ideal agent for treating severe thyrotoxicosis or thyroid crisis when a rapid decrease in plasma 
T4 and T3 is desirable. 
 
                 The iodine-containing oral cholecystographic contrast agents (OCAs) act by 
inhibiting the peripheral conversion of T4 to T3 and thus lower their concentration in the 
plasma and it includes  
 
• Sodium ipodate (Oragrafin) 
•  Iopanoic Acid (Telepaque) 
•  Tyropanoic Acid (Bilopaque) 
•  Iocetamic Acid (Cholebrine) 
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4. Radioactive Iodine: 
                 Millicurie amounts of 131I ( Iodotope I-131) are used for thyroid ablation in the 
management of hyperthyroidism. 131I is concentrated selectively by the thyroid gland. The 
ablative effect is exerted primarily through β particle emissions, which destroy thyroid tissue.  
 
5. Lithium carbonate: 
                 Lithium inhibits thyroidal incorporation of I- into Tg, as well as the secretion of 
thyroid hormones, but it does not inhibit the activity of the Na+–I- symporter or the 
accumulation of I- within the thyroid.(60) 
 
 Thyroid Surgery: 
           A thyroidectomy is an operation that involves the surgical removal of all or part of 
the thyroid gland. Thyroidectomy is an effective method of therapy for patients in whom RAI 
or thioamides are contraindicated; for those with large goitres, causing cosmetic 
disfigurement; for those with suspected malignancies; and for selected pregnant and 
paediatric patients. The ideal surgical end point is a 3 to 8gm remnant of thyroid tissue, left 
after surgery that produces neither a recurrence of the thyrotoxicosis nor hypothyroidism. 
 
A subtotal thyroidectomy is the most popular form of surgery performed for 
hyperthyroidism because it offers the best chance of euthyroidism. Others advocate a total 
thyroidectomy, for which hypothyroidism is a recognised side effect of surgery for which 
levothyroxine replacement will be needed lifelong.(61) 
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1.16. SPECIAL TREATMENT CONSIDERATIONS 
 
 Exophthalmos 
                 Exophthalmos is the bulging of the eye anteriorly of the orbit. If left untreated 
exophthalmos can cause the eyelids to fail to close during sleep leading to corneal dryness 
and damage. Another possible complication is a form of redness or irritation called superior 
limbic kerato conjunctivitis, where the area above the cornea becomes inflamed as a result of 
increased friction during blinking. 
 
Various degrees of the following signs and symptoms occur: 
• Edema and swelling of the lids and periorbital tissue, causing chemosis, excessive 
tearing, photophobia and conjunctivitis. 
• Proptosis, which produces a wide-eyed staring expression. Cornea scarring and 
ulceration can occur if the proptosis causes the lid to remain open, exposing and 
drying out the eye during sleep. 
• Limitation of the extraocular eye movements from paralysis of the extraocular 
muscles. 
• Blindness may occur from venous congestion and haemorrhage of the retina and optic 
nerve. (62) 
TREATMENT 
• Some clinicians favour thyroid ablation with either RAI or surgery to 
remove the gland. 
• The grittiness of the eye can be treated with hypromellose eye drops 
• severe complications from proptosis, diplopia or visual failure should be 
treated with high dose prednisolone(60-120md/day) until symptoms 
resolve 
 
 
TABLE NO: 2.2 
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 Thyroid Storm 
                 It’s an exaggerated form of thyrotoxicosis. It’s a medical emergency characterized 
by 
a) Acute onset of high fever 
b) Cardiovascular symptoms like tachycardia, shock, tachyapnea, arrhythmia and 
congestive heart failure. 
c) Gastro intestinal symptoms like diarrhoea and vomiting 
d) CNS symptoms like agitation and psychosis.(63) 
 
 
 
 
TABLE NO: 2.3 
 Atrial Fibrialltion 
                 Hyperthyroidism can cause new onset or worsening of atrail fibrialltion and 
congestive heart failure. The atrial fibrialltion is often difficult to control until euthyroidism is 
achieved. 
                 
 
TREATMENT 
 
a) Support of vital functions with sedation, O2, fluids, antipyretics, 
treatment of infection, electrolyte balance. 
b) Use of thioamide and iodides to block synthesis and release of 
hormones. 
c) Blockage of metabolic effects by using propranolol 
d) Remove circulating hormone by plasmapheresis, exchange 
transfusion and dialysis when response to drug is failed. 
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                  A combination of medications including β blocker, calcium channel blocker and a 
large dose of digoxin is required to slow the heart. Anticoagulant with caumadin is 
recommended in those with valvular disease and heart disease because of high incidence of 
emboli.(64) 
 
 Neonatal thyrotoxicosis 
                 Neonatal thyrotoxicosis results from stimulation of the foetal thyroid by 
transplacental passage of thyroid receptor stimulating antibodies from the maternal 
circulation. The infants require supportive measures including sedation, cooling, electrolyte 
replacement and treatment with thioamides, iodides or β- blockers.(65) 
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1.17. HERBAL THERAPY FOR HYPER THYROIDISM 
                 Four herbs are commonly suggested by Western herbalists, other practitioners of 
complementary and alternative medicine and naturopathic medical textbooks for treating 
hyperthyroidism.(66) Three herbs appear to have effects on thyroid hormone-- lemon balm 
(Melissa officinalis, Lamiaceae), bugleweed (Lycopus virginicus, Lamiaceae), and gromwell 
(Lithospermum officinale, Boraginaceae); and one appears to reduce secondary symptoms of 
hyperthyroidism (heart palpitations and tachycardia), motherwort (Leonurus cardiaca, 
Lamiaceae).(67) 
 Bugleweed (Lycopus virginicus)  and Gypsywort  (Lycopus europaeus) 
                 These two closely related herbs have been used traditionally for the treatment of 
overactive thyroid conditions. Lycopus is naturalised in some wet areas of NZ and Australia. 
Lycopus appears to have several mechanisms of action(68) 
• Inhibition of receptor binding of TSH and thyroid auto-antibodies to TSH receptors. 
• Inhibition of iodine metabolism and release of thyroid hormone, by cyclic AMP 
inhibition at thyroid membrane. 
• Oral doses of Lycopus inhibit the conversion of T4 to T3 in the peripheral tissues.  
Hence, Lycopus is an essential herb to use in people with hyperthyroidism.(69) 
 
 Lemon balm ( Melissa officinalis) 
                 Lemon balm is another very useful and safe herb to use in hyperthyroidism. Apart 
from its antithyroid actions, it also has a nervine relaxant effect which can be useful for the 
anxiety/irritability that often accompanies hyperthyroidism. 
Possible mechanisms of action: 
• Inhibits the binding of TSH and thyroid auto-antibodies to TSH receptors.  
• Inhibition of conversion of T4 to T3 by blocking the enzyme responsible for this 
conversion.(70) 
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 Motherwort   (Leonorus cardiac) 
                  Motherwort is traditionally known as a heart tonic and uterine stimulant. 
Motherwort can be beneficial for treating some of the symptoms of hyperthyroidism such as 
anxiety, palpitations and increased heart rate.(71,72) 
  
 Gromwell  (Lithospermum officinal) 
                  Gromwell is perhaps best known for its anti-gonadotrophic actions. It does appear 
to have antithyroid actions similar to lemon balm, by inhibiting the binding of TSH and 
thyroid auto-antibodies to TSH receptors. 
 
 Self-heal (Prunella vulgaris) 
                 Self heal is one of the richest sources of rosmarinic acid (5%). This compound can 
exert antithyroid activity after oxidation. Theoretically, therefore, self-heal may have some 
anti-thyroid activity(73) 
 
Other Herb 
• Emblica officinalis (74) 
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Chapter -2 
2.1. REVIEW OF LITERATURE 
 
 
Salman khan M, et al., (2013) investigated chemotherapeutic potential of Boerhaavia 
diffusa linked from ancient time to the present with the scope in future. Furthermore a 
recent update on mechanistic approaches of B. diffusa has also been discussed. Based on 
antioxidant & antdiabetic characteristic it is hypothesized that Boerhaavia diffusa might 
exhibit antiglycating properties as well.(75) 
 
Kanjoormana Aryan Manu, et al.,( 2009) evaluated Immunomodulatory activities of 
punarnavine,an alkaloid from B. diffusa  using Balb/C mice. Punarnavine enhanced 
proliferation of splenocytes, thymocytes and bone marrow cells both in presence and 
absence of specific mitogens in vitro and in vivo. More over administration of 
Punarnavine significantly reduced the LPS induced elevated levels of pro inflammatory 
cytokines such as TNF-α, IL-1β and IL-6 in mice. (76) 
 
Mandeep kaur, et al.,(2009) investigated the methanolic extract of Boerhaavia diffusa 
roots & its different fraction including liriodendrin rich fraction for exploring the possible 
role of liriodendrinrich in its anticonvulsant activity. These finding concluded that 
observed anticonvulsant activity was due to calcium channel antagonistic action as this 
activity was retained only in liodendrin rich fraction which posse’s significant 
anticonvulsant activity of liriodendrin in BAY K-8644 induced seizures. (77) 
 
 Sandhya.k, et al., (2010) had conducted a comparative study of hydro alcoholic extract 
and  poly herbal formulation of Boerhaavia diffusa for their  anti stress activity using cold 
restrainst stress model.Due to cold restrain stress there was imbalance in  the level of 
biochemical parameter like glucose, triglycerides, cholesterol, SGOT, SGPT which were 
near normalized following the administration of HEBD &  PHF-09. HEBD and PHF-09 
were found to have comparable anti stress activity. (78) 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 36 
 
Surendar. k. Pareta et al.,( 2011) found out the effects of pre treatment of aqueous 
extract of Boerhaavia diffusa root( 200-400 mg/kg /day) in repeated dose acetaminophen 
nephrotoxic rats for 14 days. Acetaminophen administration characterized by significant 
increase in Blood urea nitrogen (BUN), serum creatinine and increased level of kidney 
malondialdehyde prolein thiol, along with depletion of SOD, CAT, GPX and GSH. 
.Histopathological changes showed significant structural damage to kidney. The result 
suggest that Boerhaavia diffusa has the potential in preventing the acetaminophen 
induced Nephrotoxicity. (79) 
 
Ramachandran. y.L, et al.,(2011) evaluated the hepatoprotective properties of 
petroleum ether extract, Methanolic extract and isolated compound of B. diffusa & A. 
lanata against carbon tetra chloride induced hepatic damage in rats. This study reveals 
that different dose of plant extract offer significant protection of serum test and liver 
histology. (80) 
 
Shisode. k.s, et al.,(2011) had studied that different extract of roots of Boerhaavia diffusa 
for invitro antioxidant activities & phytochemical screening. Among these there extract, 
ethanolic extract had shown better antioxidant activity & phytochemical screening 
revealed the presence of carbohydrate saponins, proteins, flavonoids, steroids, fats & 
alkaloid. (81) 
 
Gopal. T.k, et al., (2010) evaluated invitro antioxidant activities of chloroform, ethanol 
&  ethyl acetate fraction of B. diffusa.L which might have improved it’s hepatoprotective 
action. The extract found to have significant Nitric oxide and DPPH radical scavenging 
activity. The result suggest  that roots of Boerhaavia diffusa were found to reveal 
antioxidant potential which support the use of plant in traditional medicine. (82) 
 
Apurba sarker Apu. et al., (2012) investigated the bioactivities of crude n-hexane, ethyl 
acetate and methanolic extract of aerial parts of the Boerhaavia diffusa linn and its 
phytochemical analysis. Methanolic extracts showed higher anti oxidant, thrombolytic 
activity and less cytotoxic activity than that of n-hexane & ethyl acetate extract of 
Boerhaavia diffusa. All the extract showed significant inhibitory activity aqainst candida 
albicans at a concentration of 1000µg/disc. These findings suggest that plant could be 
important source of medicinally important natural compound. (83) 
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Shukla Anamika and Gupta Rakesh kumar, (2011) studied the effects of aqueous 
extract of Boerhaavia diffusa  roots and leaves on blood sugar level is Alloxan induced  
diabetic  rats. These studies conclude that aqueous extract of B. diffusa have shown 
hypoglycemic effect may be due to presence of glycosides, flavonoids, tannins and 
saponin in the extract.(84) 
 
Suralkas A.A et al.,(2012 ) investigated antihistamine activity of ethanolic extract  of 
Boerhaavia diffusa linn roots using isolated goat tracheal chain and histamine induced 
bronchoconstriction in Guinea pig Boerhaavia diffusa significantly inhibited dose 
dependent contraction of goat tracheal chain produced by histamine and also showed 
significant protection by prolonging preconvulsion dyspnoea time in guinea pigs.Thus 
Boerhaavia diffusa showed antihistaminic and bronchodilating activity against histamine 
and hence posses potential role in treatment  of asthma. (85) 
 
Surendran. k, et al., (2010) evaluated anti urolithiatic activity of Boerhaavia diffusa lina 
root aqueous extract and rationalize it’s use in treating renal stone. The lithogenic 
treatment causes weight loss, hyperoxalurea and impairment  of renal function. 
Boerhaavia diffusa linn causes diuresis and hasten the process of dissolving crystals and 
helps in mechanical expulsion of  stones and improve the renal function by removing the 
waste product and decrease oxalate excretion by interfering with metabolism. Results of 
this study indicate Boerhaavia diffusa lina posses antiurolithiatic that possibly mediated 
through diuretic and hypo-oxaluric effects. (86) 
 
Mahesh, A.R, et al.,( 2012) had conducted a detailed study on Boerhaavia diffusa for it is 
medicinal importance. Various phytochemical ,pharmacological ,experimental and 
clinical investigation are done on Boerhaavia diffusa. This include evidence based over 
view of pharmacological, phytochemical properties of aerial parts & the roots of 
Boerhaavia diffusa which may be helpful to establish a standard natural drug for further 
studies. (87) 
 
Meena, A.K, et al., (2010) investigated the standardized and phytochemically evaluated 
aqueous and hydroalcoholic extracts of Boerhaavia diffusa. It involve pharmacognostical 
examination of morphological and microscopical characters and phytochemical 
investigation of Boerhaavia diffusa including determination of loss on drying, ash values, 
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TLC and extractive values. The qualitative chemical examination revealed the presence of 
various phytoconstituents like carbohydrate, ,saponins,phenolic compound and mucilage 
in the extract. (88) 
 
Babita Aqrawal,et al., (2011) have investigated a review on it is phytochemical and 
pharmacological profile  Phytochemical studies had shown the presence of rich source of 
alkaloids, steroids and flavones. pharmacological research  explains hepatoprotective, 
diuretic, anti inflammatory ,anti-stress and immunomodulation anti fertility, 
antimicrobial, antiviral, and insecticidal activities. In conclusion Boerhaavia diffusa 
contain biologically active compounds that may serve as candidate for new drugs in the 
treatment and prevention of human  live stock diseases. (89) 
 
Goyal.B.M et al ., (2010) analyzed an overview of pharmacological potential of 
Boerhaavia diffusa. It covers various physiology, pathology of disease and their therapies. 
This article includes evidence based information regarding pharmacological activity of 
this plant. It has many ethanobotanical users and is medicinally used in the traditional 
Ayurvedic system. (90) 
 
Bhavin, A, et al.,( 2013)  investigated the effect of hydro alcholic extract of roots of 
Boerhaavia diffusa in experimental Beningn prostatic hyperplasia in rats. Body weight, 
prostate weight, bladder weight and serum testosterone were measured and histological 
studies were carried out. The result suggested that treatment with Boerhaavia diffusa may 
improve  symptoms of disease and inhibit the increased prostrate sign. Invitro study 
implies that herbal extract had  a beneficial effect on prostatic smooth muscles which 
relieve the urinary symptom and disease. (91) 
 
 Krishna murti, et al., (2001) evaluated antidiabetic activity of ethanolic extract of roots 
of Boerhaavia   diffusa against streptozocin induced experimental rats. Blood glucose 
level were determined on 0, 7th, 14, & 21st day after oral administration. The effect of 
ethanolic extract of B.diffusa on serum lipid profile like total cholesterol, triglycerides, 
LDl,VLDL, HDL were also measured in diabetic and non diabetic rats.The ethanolic 
extract of Boerhaavia diffusa was found to reduce blood sugar level in streptozocin 
induced diabetic rats. There was significant reduction in total cholesterol,LDL, VLDL, & 
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improvement in HDL cholesterol in diabetic rats. The results indicated that Boerhaavia 
diffusa posses a hypoglyceamic & antihyperlipideamic effect. (92) 
 
Ajmire. P.V, etal., (2011) had conducted study of alcoholic & aqueous extract of whole 
plant of Boerhaavia diffusa against DMNO induced liver cirrhosis in rat’s model. The 
activity was assessed using ILS, histopathological studies of liver, biochemical & 
heamatological studies. EEBD & AEBD shows significant increase in survival time, a 
decrease in cirrhotic nodules. The biochemical & heamatological parameter were also 
corrected by EEBD & AEBD in DMN induced rats. However out of these two extract, 
EEBD shows maximum anti cirrhotic effect than AEBD. (93) 
 
Venkatesh. P, et al (2012) evaluated analgesic & antipyretic activity of various doses of 
alcoholic extracts of stem & leaves of Boerhaavia diffusa & leaves of Anisochilus 
carnosus. Tail immersion method & Hot plate in mice were studied for analgesic activity. 
Alcoholic extract of Boerhaavia diffusa had shown significant analgesic & antipyretic 
activity. (94) 
 
Mohammed Khalid, et al., (2012) had studied pharmacological evalution and qualitative 
analysis of Boerhaavia diffusa L. root. Various parameters like macroscopy, microscopy, 
fluorescence analysis as well as extraction value and qualitative phytochemical screening 
of different extraction were studied. The major components of extractions like total 
phenolic, total flavonoids were also estimated. (95) 
 
Venkatesh. P, et al., (2012) evaluated a study on alcoholic extract of stem and leaves of 
Boerhaavia diffusa and leaves of Anisochilus carnosus on ccl4 induced hepatotoxicity in 
rats. Different dose levels administered. Biochemical parameters of liver like SGOT, 
SGPT, serum alkaline phosphatase, total and direct serum bilurubin were determined. It 
was concluded that the alcoholic extract of AEBD and AEAC possess hepato protective 
activity against ccl4 induced hepatotoxicity in rats. (96) 
 
 
 
 
  
 
SCOPE OF THE 
PRESENT WORK 
 
 
 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 40 
 
 
CHAPTER-3 
3.1. SCOPE OF THE PRESENT WORK 
 
The last couple of decades have seen a tremendous increase in interest in the 
biological properties of natural products as a means to identify novel compounds that could 
have potential in clinical medicine. To that end, flavonoids and flavonoid-like compounds 
percolate to the top due to their presence in diet constituents and reported beneficial effects 
on diverse biological processes and disease conditions. It has previously been reported that 
the consumption of flavonoids and some phenolic acids by experimental animals induced 
enlargement and histological changes in the thyroid gland. Ethanopharmacological studies on 
such herb, medicinally important plants continue to interest investigators throughout the 
world.  One such plant, Boerhaavia diffusa linn invites attention of the researchers worldwide 
for its pharmacological activities. 
The present investigation was undertaken to study the effect of the potential 
anthithyroid activity of Hydro alcoholic extract of Boerhaavia diffusa on L-thyroxine induced 
hyperthyroidism in wistar rats. Hydro alcoholic extract of Boerhaavia diffusa contain several 
medicinally active compounds including polyphenols(stilbenes and flavanoids),  tannins and 
anthocyanins.. The different parts of the plant Boerhaavia diffusa has been used in different 
system of traditional medication for the treatment of diseases and ailments of human beings. 
The effects produced by the extract on different parameters were compared with propyl thio 
uracil. 
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CHAPTER-4 
AIM 
To identify a plant with potential antithyroid activity and to compare the effect of 
Hydro alcoholic extract of Boerhaavia diffusa (HAEBD) on L-thyroxine induced 
hyperthyroidism in rats with the standard drug propylthiouracil. 
 
OBJECTIVES 
 Evaluation of antithyroid activity of Hydro alcoholic extract of Boerhaavia diffusa 
against l-thyroxine induced hyperthyroid model.  
 Compare antithyroid potential with propylthiouracil. 
 
PLAN OF WORK 
 Collection of plant material and preparation of plant extract. 
 Evaluation of anti-thyroid activity and their effects on the thyroid hormones. 
a. Selection, grouping and acclimatization of the animals. 
b. Induction of hyperthyroidism in rats by using l-thyroxine 
c. Treatment protocol 
d. Evaluation of biological parameters 
e. Histopathological examination of thyroid gland of animals 
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CHAPTER-5 
PLANT PROFILE 
 
 
Figure no : 5 BOERHAAVIA DIFFUSA 
 
  
 
Figure no : 6  ROOT OF BOERHAAVIA DIFFUSA 
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SCIENTIFIC  CLASSIFICATION: 
SCIENTIFIC NAME         :   Boerhaavia diffusa Linn. Syn. B. repens; B. repens var. diffusa 
FAMILY                             :    Nyctaginaceae 
FAMILY NAME                :    Hog weed, Horse Pursl                                                
 
TAXONOMICAL CLASSIFICATION: 
                                                     
KINGDOM                                 :  Plantae 
FAMILY                                    :  Nyctaginaceae 
DIVISION                                 :   Magnoliophyta 
CLASS                                      :   Magnoliopsida 
ORDER                                     :   Caryophyllales 
GENUS                                     :   Boerhaavia 
SPECIES                                   :  Boerhaavia diffusa 
 
COMMON NAMES: 
Raktapunarnava, Shothaghni, Kathillaka, Kshudra, Varshabhu, Raktapushpa, Varshaketu, 
Shilatika. 
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VERNACULAR NAMES: 
BENGALI                         :       Raktapunarnava 
ENGLISH                         :       horse purslene, hog weed 
HINDI                               :      Gadapurna, Lalpunarnava 
KANADA                         :       Sanadika, Kommeberu, Komma 
MALAYALAM                :       ChuvannaTazhutawa 
TAMIL                              :       Mukurattai (Shihappu) 
TELUGU                           :       Atikamamidi, Erragalijeru 
 
 
GEOGRAPHICAL DISTRIBUTION: 
 
 Boerhaavia diffusa is also indigenous to India; it is found throughout the warmer parts 
of the country up to an altitude of 2000 m in the Himalayan region. The genus Boerhaavia 
has several species, and is distributed in the tropical, subtropical, and temperate regions of the 
world.158It is found in Australia, China, Pakistan, Sudan, Sri Lanka, Egypt, SouthAfrica, USA 
and in several countries of the Middle East. Out of the 40 species of this genus, 6 species are 
found in India – B. diffusa, B. chinensis, B. erecta, B. repens, B.rependa, and B. rubicund.(97) 
 
ORIGIN AND HABITAT:  
Boerhaavia diffusa is a perennial creeping weed, prostrate or ascending herb, up to 1 
m long or more, havingThis is found throughout India. It grows up to an altitude of 70 
centimeters especially during the rainy season. It has a large root system and produces yellow 
and white flowers. It can be found in many tropical and warm-climate countries.(98) 
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USEFUL PARTS:         
Root, leaves&seeds,stem,flowers, fruits 
 
DESCRIPTION:  
Boerhaavia diffusa is a perennial creeping weed, prostrate or ascending herb, up to 1 
m long or more, having spreading branches. 
 
The roots are very variable diffusely branched low spreading or creeping herbaceous 
perennial with an elongated fusiform or tapering tap root. The roots are stout and fusiform 
with a woody. 
 
The stems are numerous; 1-2 m long &the stem is prostrate, woody or succulent, 
cylindrical, often purplish, hairy, and thickened at the nodes.(99) 
 
Leaves are simple, thick, fleshy, and hairy, arranged in unequal pairs, green and 
glabrous. The shape of the leaves varies considerably – ovate-oblong, round, or subcordate at 
the base and smooth above.  The leaves are simple, opposite, short petiolate, exstipulate, 
unequal in each pair, 2.5-5 cm long by 1-4.5 cm wide, oblong or suborbicular, acute, obtuse 
or rounded at apex, cordate, rounded or truncate at base, entire or wavy along the margin, 
subfleshy, glabrous or sparingly hairy above, silvery white beneath, petioles 0.7-3 cm long, 
slender, deeply grooved above.(100) 
 
 The flowers are small, regular, sessile or subsessile, pale rose to pink, in irregular 
clusters of 4-10, small umbels on extra axillary peduncles.(101)  
 
The fruits are very small, one seeded and enclosed in persistent lower half the 
perianth. The perianth is covered with sticky glandular hairs.  
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Part A perennial herb from a fusiform root 
Plant Boerhaavia diffusa  
Leaves Opposite or sub-opposite, two of a node unequal, broadly ovate or sub-
orbicular, obtuse to rounded or sub-cordate at the base. 
Stem Prostrate, decumbent or ascending, 4-10 cm long, rather slender, 
divaricately branched 
Flowers In pendunculate, glomerulate clusters arranged in slender, long stalked, 
axillary or terminal corymbs 
Fruit Ovoid or sub-ellipsoid, rounded above, slightly cuneate, below, broadly 
and bluntly 5-ribbed, very glandular throughout 
Flowering and 
Fruiting 
Throughout the year in Indian conditions 
 
PHYTOCHEMICALS: 
Boerhaavia diffusa contains a large number of phytoconstituents, namely flavonoids  
alkaloids, steroids, triterpenoids, lipids, lignins,carbohydrates proteins and glycoproteins .(102) 
 
• Plant also includes a series of rotenoidsi.eboeravinones from roots of the plant viz., 
Boeravinone (A-F) (103-105) 
• Punarnavoside, a phenolic glycoside, is reportedly present in roots.C-methyl flavone 
also has been isolated from Boerhaavia diffusa roots.(106) 
• Two known lignans viz., liriodendrin and syringaresinol mono-β-D-glycoside 
isolated(107) 
• Presence of a purine nucleoside hypoxanthine 9-L-arabinose(108) 
dihydroisofuroxanthone-borhavine(109), phytosterols(110) have been isolated from the 
plant.  
• It contains about 0.04 % of alkaloids known as punarnavine and punernavoside, an 
antifibrinolytic agent. 
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• It also contains about 6% of potassium nitrate, an oily substance,                       
and ursolic acid. (111) 
• The seeds of this plant contain fatty acids and allantoin and the roots contain 
alkaloids.(112) The green stalk of the plant has also been reported to contain boerhavin 
and boerhavic acid. 
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CHAPTER-6 
EXPERIMENTAL DESIGN 
Experimental Models 
For the study of anti-thyroid activity of   HAEBD, an experiment model is selected in 
such a way that it would satisfy the following: 
 The animal should develop hyperthyroidism rapidly 
 Pathological changes in the site of induction should result from damage to the 
follicular cells of thyroid 
 The symptoms should be ameliorated or prevented by a drug treatment effective in 
humans 
 The drug tested must be administered orally 
 Drug dosage should approximate the optimum therapeutic range for human, scaled the 
test animal weight. 
Selection of Laboratory Animal 
 Rats are the most commonly used animals in the study of thyroid disorders 
 Animals such as sheep, cats, dogs ,rabbit and guinea pigs are also used 
 In the present study rats have been used because, the thyroid hormone production and 
metabolism of rat resembles to that of humans which is believed to contribute to 
hyperthyroidism studies 
Materials and Methods 
Animals   : Albino Wistar Rats (190-240gm) 
Drugs       : Hydro Alcoholic Extract of  Boerhavia diffusa  
                : L-Thyroxine (T4) (Sigma,USA) 
                : Propylthiouracil (Macleods Pharmaceuticals Ltd) 
                 The study was approved by Institutional Animal Ethics committee (IAEC) of K.M. 
College of Pharmacy, Uthangudi, Madurai, which is registered with Committee for the 
Purpose of Control and supervision of Experimental Animals (CPCSEA), Government of 
India,(Registration number and date of registration:661/02/c/CPCSEA & 19/07/2002. 
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SELECTION AND ACCLIMITIZATION OF ANIMALS 
                 Adult male wistar rats (6week old) weighing 190–240 g were used in the 
experiments after allowing 15 days acclimatization. The animals were allocated four per 
polycarbonate cage in a temperature (20–25◦C) and humidity (40–45%) controlled room. The 
light: dark cycle was 12 hr: 12 hr and normal rodent pellet diet and water were supplied 
during acclimatization, free to access. 
 
INDUCTION OF HYPERTHYROIDISM 
After acclimatization, hyperthyroidism was achieved by daily oral administration of 
L-Thyroxine (T4) (Sigma,USA) at a dose of 600µg/kg for 12 consecutive days according to 
the previous established method .(113) 
 
 Levothyroxine acts like the endogenous thyroid hormone thyroxine (T4, a tetra-
iodinated tyrosine derivative). It is a synthetic form of the thyroid hormone thyroxine, which 
is normally secreted by the follicular cells of the thyroid gland. L-thyroxine is commonly 
used to produce hyperthyroidism in experimental animals due to its ability to convert into t3, 
the active metabolite in the liver and kidney by the enzyme 5’-deiodinase. 
Preparation of Drugs: 
• Hydro-alcoholic extract of boherhavia diffusa is dissolved in sterile water. 
• Propyl thiouracil tablets were weighed, powdered and triturated with saline. 
• L-thyroxine tablets were weighed and dissolved in distilled water. 
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TREATMENT PROTOCOL 
 
                 Animals were randomly divided into 5 groups of 6 rats each after 12 days L-
thyroxine (T4) treatments as follows 
 
Group-1   Served as normal control received 10ml/kg of normal saline. 
  
Group-2   Served as hyperthyroidoism control received distilled water orally for 15 days. 
 
Group-3   Served as treatment control received 10mg/kg of propyl thiouracil(PTU),orally    
                     for 15 days.(114) 
 
Group-4   Served as treatment control received 200mg/kg of Hydro Alcoholic Extract of   
 
                     Boerhaavia  Diffusa orally for 15 days. 
 
Group-5   Served as treatment control received 400mg/kg of Hydro Alcoholic Extract   
 
                    of Boerhaavia Diffusa orally for 15 days.(115) 
 
 
               After  12 days of L- thyroxine treatment, propyl thio uracil was injected 
intraperitoneally to G3 group in a volume of 5ml\kg dissolved in saline for 15 days to G3 
group  and  plant extract of  low dose and  high dose  administered to G4 and G5 group for 15 
days.  The dosages of BD extracts used in this study were selected based on the previous 
report, in which 400 mg/kg of BD extracts showed enough in vivo pharmacological effects in 
rats  and propyl thio uracil 10 mg/kg was also selected based on the previous in vivo efficacy 
test on the L-THYROXINE(T4)-induced hyperthyroidisms in rodents.. Equal volume of 
saline was subcutaneously treated in intact control rats instead of L-THYROXINE (T4), and 
equal volume of distilled water was orally administered in intact and L-THYROXINE (T4) 
control rats, instead of BD extracts or propyl thio uracil (116) 
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METHADOLOGY 
                 After 15 days of treatment, the blood was collected from the retro-orbital plexus 
puncture of all groups of overnight fasted rats using micro capillary. The serum was 
separated for the estimation of thyroid hormones (TSH, T3, and T4) and liver enzymes (AST, 
ALT).Then the animal was sacrificed by decapitation. The thyroid gland was immediately   
dissected out, washed in ice cold saline to remove the blood and stored in 10% formalin for 
histopathological studies. The liver was also separated and homogenised for the estimation of 
lipid peroxidation and antioxidant defense system. 
 
 
FIG NO: 7 
 
 
 
 
A- LARYNX, B-THYROID GLAND, C-SUB MANDIBULAR GLAND,  
                                            D-TRACHEA 
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CHAPTER-7 
PHARMACOLOGICAL EVALUATION 
 
Estimation of Biochemical Parameters 
 Serum Thyroid Hormones 
                 6mL of blood samples were collected into evacuated tubes, and serum was 
separated by centrifugation at 3000 rpm for 10 min at 4◦C. Separated serum was stored at 
−70◦C before analysis. Serum levels of T3, T4, and thyroid-stimulating hormone (TSH) were 
analyzed by colorimetric competitive enzyme immunoassay using individual ELISA kit 
according to Subudhi et al. , respectively.(117) 
 
 Serum Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 
Serum AST and ALT concentrations were measured by automated blood analyzer  
according to previous method.(118) 
 
 Liver Lipid Peroxidation (LPO) 
                 Separated liver tissues were weighed and homogenized in ice-cold 0.01M Tris- 
HCl (pH 7.4), and then centrifuged, at 12,000 g for 15 min as described by Kavutcu et al.(119) 
The concentrations of liver LPO were determined by estimating malondialdehyde (MDA) 
using the thiobarbituric acid test at absorbance 525 nm, as nM of MDA/mg protein .(120) 
 
 Liver Antioxidant Defense Systems 
                 Prepared homogenates were mixed with 0.1mL of 25% trichloroacetic acid 
(Merck, CA, USA), and then centrifuged at 4,200 rpm for 40 min at 4◦C. Glutathione 
(GSH)(121) contents were measured at absorbance 412nm using 2-nitrobenzoic acid 
(Sigma,MO, USA).Decomposition of H2O2 in the presence of catalase was followed at 
240nm (122). Catalase activity was defined as the amount of enzyme required to decompose 
1nM of H2O2 per minute, at 25◦C and pH 7.8. Results were expressed as U/mg protein. 
Measurements of SOD activities were made according to Sun et al.(123) SOD estimation was 
based on the generation of superoxide radicals produced by xanthine and xanthine oxidase, 
which react with nitrotetrazolium blue to form formazan dye.SOD activity was then 
measured at 560nm by the degree of inhibition of this reaction, and was expressed as U/mg 
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protein. One unit of  SOD enzymatic activity is equal to the amount of enzyme that 
diminishes the initial absorbance of nitroblue tetrazolium by 50% during 1min. 
 
Histology 
                 The sampled thyroid gland tissues were fixed in 10% neutral buffered formalin. 
After paraffin embedding, 3–4 μm serial sections were prepared. Representative sections 
were stained with hematoxylin and eosin (H&E) for an optical microscopy examination. 
Subsequently, the histological profiles of the organs were observed. The mean cross thickness 
of thyroid gland, thyroid follicle, and follicular lining epithelium were measured using an 
automated image analysis process. 
 
Statistical Analysis 
                 Numerical data are presented as mean± S.E.M. of six rats, the obtain data was 
analyzed using a one way ANOVA test followed by Newmann Keuls multiple range tests. 
Statistical analyses were conducted using graphpad version 3.1. P values < 0.05 were 
considered significantly different. 
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Table No: 3 
SERUM THYROID HORMONE LEVELS IN THE L-THYROXINE (T4) AND 
HAEBD TREATED RATS 
 
GROUPS TSH(ng/ml) T3(ng/ml) T4 (µg/ml) 
 
GP1 
 
1.92±0.16 
 
0.58±0.14 
 
53.72±5.90 
GP2  
0.70±0.07*a 
 
2.30±0.20*a 
171.84±4.80*a 
 
GP3 
 
1.46±0.12*b 
 
0.96±0.12*b 
72.30±5.35*b 
 
GP4 
 
1.30±0.10*b 
 
1.30±0.30*b 
86.12±3.10*b 
 
GP5 
 
1.36±0.11*b 
 
1.12±0.22*b 
 
78.30±4.15*b 
 
GP1- Normal; GP2- Hyper Control; GP3- Standard Control(PTU 10mg/kg); GP4- HAEBD (200mg/kg);GP5- 
HAEBD (400mg/kg) 
 
 All values are expressed as mean ± SEM for 6 animals in each group. 
 **a – Values are significantly different from Normal control (G1) at P < 0.01 
 **b – Values are significantly different from hyperthyroid control (G2) at P < 0.01 
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GRAPH 1. SERUM THYROID HORMONE LEVELS IN THE L-THYROXINE (TSH) 
AND HAEBD TREATED RATS 
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GRAPH 2. SERUM THYROID HORMONE LEVELS IN THE L-THYROXINE (T3) 
AND HAEBD TREATED RATS 
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GRAPH 3. SERUM THYROID HORMONE LEVELS IN THE L-THYROXINE (T4) 
AND HAEBD TREATED RATS 
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Table No: 4 
EFFECT OF HAEBD  ON SERUM LIVER ENZYMES LEVELS IN THE L-
THYROXINE (T4) AND HAEBD TREATED ANIMALS 
 
GROUPS AST(IU/L) ALT(IU/L) 
 
GP1 
 
120.95±5.20 
 
64.5±3.28 
 
GP2 
 
204.60±8.80*a 
 
130.55±3.75*a 
 
GP3 
 
126.90±5.45*b 
 
86.15±3.50*b 
 
GP4 
 
150.40±3.60*b 
 
96.05±4.85*b 
 
GP5 
 
138.45±3.68*b 
 
87.75±3.90*b 
 
GP1- Normal; GP2- Hyper Control; GP3- Standard Control(PTU 10mg/kg); GP4- HAEBD (200mg/kg);GP5- 
HAEBD (400mg/kg) 
 All values are expressed as mean ± SEM for 6 animals in each group. 
 **a – Values are significantly different from  Normal control (G1) at P < 0.01 
 **b – Values are significantly different from hyperthyroid control (G2) at P < 0.01 
 
 
  
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 59 
 
 
 
 
 
 
GRAPH 4. EFFECT OF HAEBD  ON SERUM LIVER ENZYMES LEVELS IN THE 
L-THYROXINE (AST) AND HAEBD TREATED ANIMALS 
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GRAPH 5. EFFECT OF HAEBD  ON SERUM LIVER ENZYMES LEVELS IN THE 
L-THYROXINE (ALT) AND HAEBD TREATED ANIMALS 
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Table No: 5 
LIVER LIPID PEROXIDATION AND ANTI OXIDANT DEFENCE SYSTEMS IN 
THE L-THYROXINE (T4) AND HAEBD TREATED RATS 
 
GP1- Normal; GP2- Hyper Control; GP3- Standard Control(PTU 10mg/kg); GP4- HAEBD (200mg/kg);GP5- 
HAEBD (400mg/kg) 
 
 All values are expressed as mean ± SEM for 6 animals in each group. 
 **a – Values are significantly different from Normal control (G1) at P < 0.01 
 **b – Values are significantly different from hyperthyroid control (G2) at P < 0.01 
 
 
 
 
GROUPS 
LIPID 
PEROXIDATION ANTI OXIDANT DEFENCE SYSTEM 
MDA(nm/mg 
protiein) 
GSH 
(nµ/mg protein) 
SOD 
U/mg protein 
CATALASE 
U/mg protein 
 
GP1 
 
2.07±0.12 
 
35.27±3.95 
 
22.65±2.04 
 
       30.27±2.81 
 
GP2 
 
4.75±0.30*a 
 
12.15±1.55*a 
 
52.61±3.04*a
 
48.23±2.32*a 
 
GP3 
 
3.47±0.40*b 
 
17.67±2.84*b 
 
28.05±2.63*b
 
34.14±1.97*b 
 
GP4 
 
2.8±0.30*b 
 
24.24±2.48*b 
 
31.07±3.06*b
 
37.50±2.32*b 
 
GP5 
 
2.57±0.16*b 
 
21.82±1.17*b 
 
29.12±1.96*b
 
35.40±4.66*b 
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GRAPH 6. LIVER LIPID PEROXIDATION AND ANTI OXIDANT DEFENCE 
SYSTEMS IN THE L-THYROXINE (MDA) AND HAEBD TREATED RATS 
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GRAPH 7. LIVER LIPID PEROXIDATION AND ANTI OXIDANT DEFENCE 
SYSTEMS IN THE L-THYROXINE (GSH) AND HAEBD TREATED RATS 
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GRAPH 8. LIVER LIPID PEROXIDATION AND ANTI OXIDANT DEFENCE 
SYSTEMS IN THE L-THYROXINE (SOD) AND HAEBD TREATED RATS 
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GRAPH 9. LIVER LIPID PEROXIDATION AND ANTI OXIDANT DEFENCE 
SYSTEMS IN THE L-THYROXINE (CATALASE) AND HAEBD TREATED RATS 
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HISTOPATHOLOGICAL STUDIES 
 
FIG NO: 8 
 
 
Thyroid gland section of GP1 rats (normal control) showing follicles lined by cuboidal 
epithelial cells filled with 60-70% colloid. 
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FIG NO: 9 
 
 
 
Thyroid gland section of GP2 rats (hyperthyroid control) showing follicles lined by cuboidal 
epithelial cells filled with 40-50% colloid. 
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FIG NO: 10 
 
 
 
Thyroid gland section of GP3 rats (standard control at a dose of 10mg/kg) showing follicles 
lined by cuboidal epithelial cells filled with 80-90% colloid. 
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FIG NO: 11 
 
 
 
Thyroid gland section of GP4 rats (HAEBD extract at a dose of 200mg/kg) showing follicles 
lined by cuboidal epithelial cells filled with 50-60% colloid. 
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FIG NO: 12 
 
 
 
Thyroid gland section of GP5 (HAEBD extract at a dose of 400mg/kg/rat) rats showing 
follicles lined by cuboidal epithelial cells filled with 70-80% colloid. 
 
 
 
 
 
 
 
 
  
 
 
RESULTS AND 
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CHAPTER-8 
RESULTS 
 
 Effects on the Serum Thyroid Hormones.  
                 L-THYROXINE (T4) treatment induced significant (P < 0.01) increase of the 
serum T3 and T4 levels and decrease of the serum TSH contents. But 400 and 200mg/kg of 
BD extracts significantly (P < 0.01) and dose-dependently normalized the changes on the 
serum T3, T4, and TSH concentrations induced by L-THYROXINE (T4) as compared with L-
THYROXINE (T4) control. PTU 10 mg/kg also normalized the serum thyroid hormone 
levels, as similar as BD extracts 200 and 400 mg/kg, in the present study (Table 3). 
 
 Effects on the Serum AST and ALT 
                Significant (P <0.01) increases of serum AST and ALT levels were detected in L-
THYROXINE(T4) control rats as compared with intact control rats, controversially, AST and 
ALT concentrations in serum of PTU and both two different dosages of BD extracts treated 
rats were significantly (P < 0.01) decreased as compared with L-THYROXINE (T4) control 
rats, respectively(Table 4). 
 
 Effects on the Liver LPO 
                 Continuous subcutaneous L-THYROXINE (T4) injection induced significant (P 
< 0.01) increase of the liver LPO. But 400 and 200mg/kg of  BD extracts significantly (P < 
0.01) and dose-dependently normalized the changes on the liver LPO induced by L-
THYROXINE(T4) as compared with L-THYROXINE(T4) control.PTU 10mg/kg also 
normalized the liver LPO comparable as BD extracts 200 and 400 mg/kg (Table 5). 
 
 Effects on the Liver Antioxidant Defense Systems 
                 In L-THYROXINE (T4) control, significant (P < 0.01) decreases of GSH contents 
were demonstrated with increases of SOD, and catalase activities as compared with intact 
control, respectively. However, both different dosages of BD extracts were dose dependently 
and significantly (P < 0.01) inhibited changes on the GSH, SOD and catalase. In addition, 
PTU also significantly (P < 0.01) inhibited the L-THYROXINE (T4) treatment-related 
changes on the antioxidant defense systems as compared with L-THYROXINE (T4) control 
(Table 5). 
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 Effects on the Organ Histopathology 
                 In histomorphometrical analysis, significant (P < 0.01) decreases of the mean 
thicknesses of cross thyroid glands and follicular lining epithelium were detected in L-
THYROXINE (T4) control as compared with intact control. These L-THYROXINE (T4) 
treatment related histopathological changes of thyroid gland, were dramatically inhibited by 
treatment of both dosages of BD extracts or PTU 10mg/kg (Fig8,9,10,11,12,). 
 
DISCUSSION 
 
                 Nowadays there is considerable interest in the potential health benefits of natural 
remedies such as medicinal plants and their extracts. One of these  extracts is HAEBD which 
has different medicinal properties including anti-inflammatory, anticarcinogenic, platelet 
aggregation inhibiting, and metal chelating properties, etc (124) . The antioxidant effects of BD 
extract has been confirmed in different studies.(125,126) Some human clinical trials investigated 
various effects of BD(127)  and there are some experimental studies about its antidiabetic 
effects (128) However, to date, there is no study on BD effects against hyperthyroidism. 
Therefore, in the present study, we investigated the effects of BD extracts on LT4-induced 
hyperthyroidisms and organ damages in comparison with those of PTU in rats with their 
possible antioxidant effects. 
 
                 It has been believed that hyperthyroidism leads to oxidative damage of various 
organs and antioxidants have been reliable and favorable effects on hyperthyroidism(129).It is 
also expected that BD extracts also may be showed beneficial effects on hyperthyroidisms 
and related organ damages.LT4-induced hypothyroidism and related liver damages were 
normalized by 15 days continuous oral treatment of BD extracts 400 and 200mg/kg from 12 
days after first LT4 treatment. Especially BD extracts enhanced the liver antioxidant defense 
systems—they dose-dependently inhibited LT4-induced increases of LPO and changes on the 
GSH contents, SOD, and catalase activities. These findings are considered as direct evidences 
that they have favorable ameliorating effect on the hyperthyroidisms and related organ 
damages induced by LT4 through antioxidant effects. The overall effects of BD extracts 400 
and 200 mg/kg were similar to that of PTU 10 mg/kg, in the present study. 
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                 Thyroid hormones (T3 and T4) are involved in the -regulation of numerous body 
functions including lipid and carbohydrate metabolism, oxygen consumption, and several 
physiological functions such as development, reproduction and growth .(130) Alterations in 
their normal levels cause some biochemical and clinical abnormalities such as 
hypothyroidism and hyperthyroidism (131). Extended exposure to the treatment with 
exogenous LT4 may alter thyroid activity by interfering with thyroid hormones synthesis, 
which provokes the disruption of thyroid axis, resulting in numerous abnormalities (132) 
Hyperthyroidism simply defined as increases of serum T3 and T4 with decrease of serum 
TSH, a pituitary hormone that regulated thyroid functions .(133,134) In the present study, LT4-
induced increases of serum T3 and T4 levels, and decreases of serum TSH concentrations 
were significantly and dose-dependently inhibited by treatment of BD extracts. In addition, 
BD extracts significantly (P < 0.01) inhibited the LT4-induced histopathological changes on 
the thyroid glands, the atrophic changes including decreases of mean thicknesses of follicular 
lining epithelium. These results are considered as direct evidences that GS extracts controlled 
the hyperthyroid states.400 and 200mg/kg of BD extracts showed comparable effects as 
compared with PTU 10mg/kg in this study.  
 
                 Liver is a major target organ for thyroid hormone with important biological and 
medical implications(135), and serious liver damages accompanied to the thyroid hormone 
imbalances regardless of hyperthyroidism or hypothyroidism (136). Clinical diagnosis of 
disease and damage to the structural integrity of liver is commonly assessed by monitoring 
the status of serum AST and ALT activities (137). Higher activities of these enzymes in serum 
have been found in response to oxidative stress induced by hyperthyroidism (138). 
Administration of BD extracts to rats resulted in inhibition of serum AST and ALT 
elevations. It has been well documented that thyroid dysfunctions increases LPO reactions 
and reactive oxygen species (ROS) (139). LPO is an autocatalytic mechanism leading to 
oxidative destruction of cellular membranes(140). Such destruction can lead to cell death and 
to the production of toxic and reactive aldehyde metabolites called free radicals, where MDA 
is the most important(141). It is known that ROS would lead to oxidative damage of biological 
macromolecules, including lipids, proteins, and DNA (142,143) and oxidative stress also 
influenced to the body adipocyte results in decreases of body fat masses and related body 
weight decreases.  MDA is a terminal product of LPO. So the content of MDA can be used to 
estimate the extent of LPO , and marked increases of liver MDA contents have been observed 
in hyperthyroid animals. GSH is representative endogenous antioxidants, prevent tissue 
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damage by keeping the ROS at low levels and at certain cellular concentrations,and accepted 
as protective antioxidant factors in tissues. 
 
                 SOD is one of the antioxidant enzymes that contribute to enzymatic defense 
mechanisms, and catalase is an enzyme catalyzes the conversion of H2O2 to H2O(155). The 
increase of some antioxidant enzymes activities such as SOD and catalase may be indicative 
of the failure of compensating the induced oxidative stress. In hyperthyroidism, it is well 
known that marked decreases of tissue GSH contents were induced, represent the decreases 
of antioxidant defense systems . Controversially, SOD and catalase activities were increase to 
remove over-produced ROS as of indication of the failure of compensating the induced 
oxidative stress. LT4-induced oxidative stresses and related organ damages were ameliorated 
by treatment of BD extracts in the present study like other previously tested antioxidants as 
direct evidenced that BD extracts have potent antioxidant effects enough to inhibited 
hyperthyroidisms. However, further mechanism studies should be conducted to clarify 
whether BD reduced oxidative damages of relative organs via improvement of thyroid 
function because dysfunction of thyroid hormones also can be lead to oxidative damages. 
 
                 In the present study, we only focused on the in vivo protective effects to 
hyperthyroidism of crud extract itself not on the active compounds. Thus, these active 
compound searches should be proceeding in future.(144) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
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CHAPTER-9 
CONCLUSION 
 
 
In conclusion, LT4-induced hypothyroidism and related liver damages were inhibited 
by oral treatment of BD extracts 400and 200mg/kg. In addition, they also enhanced the liver 
antioxidant defense systems—they dose-dependently inhibited LT4-induced increases of 
LPO and changes on the GSH contents, SOD, and catalase activities as direct evidences that 
BD extracts have favorable ameliorating effect on the hyperthyroidisms and related organ 
damages induced by LT4 through antioxidant effects. BD extracts 400 and200 mg/kg showed 
comparable effects on the LT4-induced rat hyperthyroidism as compared with PTU 10mg/kg. 
These effects of BD may help the improvement of hyperthyroidisms and accompanied 
various organ damages, but active compound searches should be proceeding in future. 
 
 
 
 
 
 
 
  
 
 
BIBLIOGRAPHY 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 76 
 
CHAPTER-10 
BIBLIOGRAPHY 
1. Anne,W., Allison,G. The endocrine system. In, Ross and Wilson ANATOMY AND 
PHYSIOLOGY. Churchill livingstone, 2001; 9:219-220. 
2. Harrisons 
3. Arthur,C, Guyton., John,E,Hall. Thyroid Metabolic Hormones. In, Text Book of 
Medical Physiology. Elsevier, 2006; 9:931-933 
4. Zoeller, R.T. Transplantel Thyroxine and Fetal Brain Development. The Journal of 
Clinical Investigatio,2003; 111 (7): 954–7 
5. Fawcett, D; Jensh. Thyroid Histology. In, Ronald Bloom & Fawcett's Concise 
Histology. Arnold Publishers, New York, 2002; 257–258. 
6. Jack De, R., Thyroid Hormone Tutorial: The Thyroid and Thyroid Hormones.  
Endocrine Pharmacotherapy Module: Thyroid Section, Summer, 2001, 1 -16 
7. Harington, C.R. Biochemical basis of thyroid function. Lancet, 1935; 1:1199–1204, 
1261–1266 
8. Moura, E., Moura,C. Regulation of Thyrotropin Synthesis And Secretion. Arq. 
Bras.Endocrinol. Metabolism, 2004; 48(1):40-52 
9. Eric, T.H., Dick, R.G. Endocrine And Metabolic Disorders: Thyroid Disorders. In, Text 
Book of Therapeutics: Drug And Disease Management. William And Wilkins Pub,6 
:310-311 
10. Wilber, J.F., Xu, A.H. The thyrotropin-releasing hormone gene: cloning, 
characterization, and transcriptional regulation in the central nervous system, heart, and 
testis. Thyroid, 1998; 8:897–901 
11. Eng, P.H., Cardona, G.R., Fang, S.L., et al. Escape from the acute Wolff-Chaikoff effect 
is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic 
acid and protein. Endocrinology, 1999; 140:3404–3410 
12. Carrasco, N. Thyroid iodine transport. In, Werner and Ingbar's The Thyroid, 
(Braverman, L.E., and Utiger, R.D., eds.) Lippincott Williams & Wilkins, New York, 
2005, 9th ed. 
13. Dohan, O., De la Vieja, A., Paroder, V., et al. The sodium/iodide symporter (NIS): 
characterization, regulation, and medical significance. Endocr. Rev., 2003; 24:48–77. 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 77 
 
14. Vaisman, M., Rosenthal, D., Carvalno, D. Enzymes involved in thyroid iodide 
Organification. Arq. Bras. Endocrinol. Metab, 2004; 48(1):9-15. 
15. Kimura,.T., Okajima, F., Sho, K., Kobayashi,I., Kondo, Y. Thyrotropin-induced 
hydrogen peroxide production in FRTL-5 thyroid cells is mediated not by adenosine 
3',5'-monophosphate, but by Ca2+ signaling followed by phospholipase-A2 activation 
and potentiated by an adenosine derivative. Endocrinology, 1995; 136: 116-123. 
16. Corvilain,B., Laurent, E., Lecomte, M., Vansande, J., Dumont, J. Role of the cyclic 
adenosine 3', 5' monophosphate and the phosphatidylinositol – Ca+2 cascade in 
mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in 
human thyroid slices. Journal of Clinical Endocrinology and Metabolism, 1994;79: 152-
159. 
17. Sun, W., Dunford, H., Kinetics and Mechanism of The Peroxidase Catalyzed Iodination 
Of Tyrosine. Biochemistry,1993; 32(5):1324-1331. 
18. Gouriprasanna, R., Mugesh, G. Thyroid hormone synthesis and anti-thyroid drugs: A 
bioinorganic chemistry approach. J. Chem. Sci, 2006;118 (6): 619–625 
19. Arvan, P. Thyroglobulin: Chemistry, biosynthesis and secretion. In, Werner and Ingbar's 
The Thyroid,. (Braverman, L.E., and Utiger, R.D., eds.) Lippincott Williams & Wilkins, 
New York, 2005, 9th Ed. 
20. Takasu, N., Yamada, T., Shimizu, Y. Generation of H2O2 is regulated by cytoplasmic 
free calcium in cultured porcine thyroid cells. Biochem. Biophys. Res. 
Commun., 1987;148:1527–1532 
21. Virion,A., Courtin, F., Deme, D., Michot, J., Kaniewski, J., Pommier,J. Spectral 
Characteristics And Catalytic Properties Of Thyroid peroxidase–H2O2 compounds in the 
iodination and coupling reactions. Archives Of Biochemistry And Biophysics, 1985;242 
(1):41-47. 
22. Ekholm,R., Bjorkman. Glutatione peroxidase degrades intracellular hydrogen peroxide 
and thereby inhibits intracellular protein iodination in thyroid epithelium. 
Endocrinology, 1997;138: 2871-2878. 
23. Braverman, L.E., Ingbar, S.H., Sterling, K. Conversion of thyroxine (T4) to 
triiodothyronine (T3) in athyreotic human subjects. J. Clin. Invest., 1970; 49:855–864 
24. Visser, T.J., Leonard, J.L., Kaplan, M.M., Larsen, P.R. Kinetic evidence suggesting two 
mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex. Proc. Natl. Acad. 
Sci. United States A., 1982; 79:5080–5084. 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 78 
 
25. Benvenga, S. Thyroid hormone transport proteins and the physiology of hormone 
binding. In, Werner and Ingbar's The Thyroid; (Braverman, L.E., and Utiger, R.D., eds.) 
Lippincott Williams & Wilkins, New York, 2005, 9th Ed. 
26. Flamant,F.B., Baxter, J.D., Forrest, D., REfetoff, S., Samuels, H., Scanlan, T.S, 
Vennstrom,B., Samarut,J. The pharmacology and classification of nuclear receptor 
superfamily: thyroid hormone receptors. Pharmacol,2006; 58(4);705-11 
27. Lazar, M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. 
Rev., 1993; 14:184–193 
28. Kliewer, S.A., Umesono, K., Mangelsdorf,D.J., Evans,R.M. Retinoid x receptors 
interacts with nuclear receptors in the retinoic acid, thyroid hormone and vitamin D3 
signalling. Nature, 1992;355(6359):446-9 
29. Salter, A.M., Fisher, S.C., Brindley, D.N. Interactions of triiodothyronine, insulin, and 
dexamethasone on the binding of human LDL to rat hepatocytes in monolayer culture. 
Atherosclerosis, 1988; 71:77–80 
30. Klein, I. The cardiovascular system in thyrotoxicosis. In, Werner and Ingbar's The 
Thyroid, 9th ed. (Braverman, L.E., and Utiger, R.D., eds.) Lippincott Williams & 
Wilkins, New York, 2005. 
31. Koibuchi, N., Jingu, H., Iwasaki, T., and Chin, W.W. Current perspectives on the role of 
thyroid hormone in growth and development of cerebellum. Cerebellum, 2003;2:279–
289. 
32. Bernal, J., Guadano-Ferraz, A.,  Morte, B. Perspectives in the study of thyroid hormone 
action on brain development and function. Thyroid, 2003; 13:1005–1012 
33. Gottilieb, P.A., Braverman, L.E. The effect of thyroid diseases on diabetes. 
Clin.Diabetes, 1994; 12:15-18 
34. David, S. C., Hyperthyroidism. Lancet, 2003; 362(9): 459-468. 
35. Li ,T. Hypothyroidism in elderly people. Geriater. Nurs.,2002; 23(2): 88-93 
36. Dunn, J.T., Dunn, A.D. Thyroglobulin: chemistry, biosynthesis, and proteolysis. In, 
Werner and Ingbar's The Thyroid. (Braverman, L.E., and Utiger, R.D., eds.) Lippincott 
Williams & Wilkins, New York, 2000; 8: 91–104 
37. Cantril,J.A., Wood,J. Thyroid and parathyroid disorders. Clinical pharmacy and 
therapeutics (Roger Walker., and Clive Edwards., eds.) Churchill Livingstone, Longman 
Singapore Publisher (Pte) Ltd, Singapore, 1996; 3:639-55 
38. Mark, P.J .V. Epidemiology of thyroid dysfunction – hypothyroidism and 
hyperthyroidism. Thyroid international, 2009;2:1-12 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 79 
 
39. Ambika,G.U., Usha,V.M. Thyroid disorders in India: An epidemiological perspective. 
Indian Journal of endocrinology and metabolism,2011;15(2):s78-s81 
40. Dayan, C., Daniels, G. Medical Progress: Chronic Autoimmune Thyroiditis. N Engl J 
Med., 1996; 335, 99-107 
41. Nussey, S., Whitehead, S. Endocrinology; An Integrated Approach. Great Britain: BIOS 
Scientific Publishers Limited., 200;1: 70-99. 
42. Weetman, A. Graves’ disease. N. Engl. J. Med., 2000; 343:1236-1248. 
43. Siegel, R., Lee, S. Toxic nodular goiter: Toxic adenoma and Toxic multinodular goiter. 
Endocrinol. Metab. Clin. North Am.,1998;27:151-168 
44. Tonacchera, M., Agretti, P., Chiovato, L. Activating thyrotropin receptor mutations are 
present in non adenomatous hyperfunctioning nodules of toxic or autonomous 
multinodular goiter. J. Clin. Endocrinol. Metab., 2000; 85:2270-2274. 
45. Roti, E., Uberti, E. Iodine excess and hyperthyroid. Thyroid,2001; 11:493-500 
46. Hamburger, J. Solitary autonomously functioning thyroid lesions. Diagnosis clinical 
features and pathogenetic considerations. Am. J. Med., 1975;58:740-748. 
47. Vansande ,J., Parma, J., Tonacchera M . Somatic and germline mutations of the TSH 
receptor gene in thyroid disease. J. Clin. Endocrinol. Metab., 1995; 80:2577-2585 
48. Koga, M., Hirometsu ,Y., Jimi, A., Toda, S., Koike, N., Nonoka, K. 
Immunohisochemical analysis of Bcl2, Bax and Bax expression in thyroid glands from 
patients with subacute thyroiditis. J. Clin. Endocrinol. Metab., 1999; 84:2221-2225. 
49. Mitsiades ,N., Poulaki, V., Mitsiades, C., Koutras, D., Chrousos, G. Apoptosis induced 
byFasL and TRAIL/APO2L in the pathogenesis of thyroid disease. Trends Endocrinol. 
Metab; 2001.,12:384-390 
50. Goroll,AH., Mulley, A.G. Primary care medicine: office evaluation and management of 
the adult patient, Lippincott Williams & Wilkins, Philadelphia,2000 4th edition. 
51. Cantril,J.A., Wood,J. Thyroid and parathyroid disorders. Clinical pharmacy and 
therapeutics (Roger Walker., and Clive Edwards., eds.) Churchill Livingstone, Longman 
Singapore Publisher (Pte) Ltd, Singapore, 1996;3:639-55 
52. Trivalle, C., Doucet ,J., Chassagne,P., Landrin, I., Kadri, N., Menard, J.F., et al. 
Differences in the signs and symptoms of hyperthyroidism in older and younger 
patients. J Am Geriatr Soc., 1996;44:50–3. 
53. Knudson, P.B. Hyperthyroidism in adults: variable clinical presentations and approaches 
to diagnosis. J Am Board Fam Pract., 1995;8:109–13 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 80 
 
54. Fitzgerald, P.A. Endocrinology. In,Current medical diagnosis and treatment.,( Tierny 
L.M, McPhee S.J, Papadakis M.A, eds. ). McGraw-Hill, New York ,2005:1102–10 
55. Taylor RB. The 10-minute diagnosis manual: symptoms and signs in the time-limited 
encounter. Lippincott Williams & Wilkins, Philadelphia, 2000. 
56. Elias S. Siraj, Update on the Diagnosis and Treatment of Hyperthyroidism. Journal of 
clinical outcomes management, 2008; 15 (6):1-10 
57. Shashank, R.J. Laboratory Evaluation of Thyroid Function. Journal of the association of 
physicians of india, 2011; 59:14-20. 
58. Jack, B.H. American Association of Clinical Endocrinologists Medical Guidelines for 
Clinical Practice For The Evaluation And Treatment Of Hyperthyroidism And 
Hypothyroidism. Endocr Pract. 2002;8(6):457-69 
59. Demers, L.M., Spencer, C.A. Laboratory medicine practice guidelines: laboratory 
support for the diagnosis and monitoring of thyroid disease. Clin. Endocrinol. 
(Oxf.), 2003; 58:138–140. 
60. Satoskat, R.S.,Bhandarkar, S.D., Nirmala, N.R. thyroid hormones and antithyroid 
drugs.in, pharmacology and therapeutics. Popular prakashan, 2005;19:856-870 
61. John,c. Thyroid and anti thyroid drugs. In,modrrn pharmacology with clinical 
applications (Charles R. Craig, Robert E. Stitzel, eds), 5th edition:742-753. 
62. Murray MT, Bongiorno PB. Hyperthyroidism. In: Textbook of Natural Medicine. Third 
Edition. London: Churchill-Livingstone, 2006 
63. Aufmkolk,M., Ingbar,J.C., Kubota,K., et al. Extracts and autooxidized constituents of 
certain plants inhibit the receptor binding and the biological activity of Graves' 
immunoglobulins. Endocrinology,1985;116(5):1687-1693 
64. Aufmkolk,M., Ingbar, J.C., Amir, S.M., et al. Inhibition by certain plant extracts of the 
binding and adenylate cyclase stimulatory effect of bovine thyrotropin in human thyroid 
membranes. Endocrinology,1984;115(2):527-534. 
65. Aufmkolk M, Kohrle J, Gumbinger H, et al. Antihormonal effects of plant extracts: 
iodothyronine deiodinase of rat liver is inhibited by extracts and secondary metabolites 
of plants. Horm Metab Res. 1984;16(4):188-192 
66. Sourgens H, Winterhoff H, Gumbinger HG, Kemper FH. Effects of Lithospermum 
officinale and related plants on hypophyseal and thyroid hormones in the rat. Int J Crude 
Drug Res. 1986;24(2):53-63. 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 81 
 
67. Sourgens, H., Winterhoff,H., Gumbinger, H.G., Kemper, F.H. Antihormonal effects of 
plant extracts, TSH-and prolactin-suppressing properties of Lithospermum officinale 
and other plants. Planta Med., 1982;45:78-86. 
68. Brinker, F. Inhibition of endocrine function by botanical agents I. Boraginaceae and 
Labiatae. J Nat Med. ,1990;1:10-18. 
69. Winterhoff, H., et al. Autoimmune diseases of the thyroid. Modern  Phytotherapist, 
1988; 4(1):1-10 
70. Brendler T, Gruenwald G, Kligler B, et al. Lemon balm (Melissa officinalis L.): an 
evidence-based systematic review by the Natural Standard Research Collaboration. J 
Herb Pharmacother. 2005;5 (4):71-114. 
71. Milkowska-Leyck K, Filipek B, Strzelecka H. Pharmacological effects of 
lavandulifolioside from Leonurus cardiaca. J Ethnopharmacol. 2002;80(1):85-90. 
72. Yanxing X. The inhibitory effect of motherwort extract on pulsating myocardial cells in 
vitro. J Tradit Chin Med. 1983;3(3):185-188 
73. Mills S. Bone K. Principles and practice of phytotherapy. Churchill Livingstone, 
2000:pg 25 
74. Panda,S., Kar, A. Fruit extract of Emblica officinalis ameliorates hyperthyroidism and 
hepatic lipid peroxidation in mice. Pharmazie., 2003;58:753 
75. Salman khan,M.,Irfan Anshari,A.,Ahamd, Firoz Akhter, Arshya Hashim Srivastava, 
A.K.  Chemotherapeutic potential of  Boerhavia diffusa Linn; A review Journal of  
Applied pharmaceutical science., 2013, 3(01): 133-139. 
76. Kanjoormana Aryan Manu, Girija Kultan. Immunomodulatory activities of 
purnarnavine an alkaloid from Boerhavia diffusa. Immunopharmacology and 
Immunotoxicology., 2009,31(3): 377-387. 
77. Mandeep Kaur, Rajesh Kumar Goel. Anti -convulsant activity of Boerhaavia diffusa; 
Plausible Role of Calcium Channel Antagonism. Evidence-Based Complementary and 
Alternative Medicine; 2009,2011(310420):7 
78. Sandhya, K., Desai, Soniya, M., Desai, Navdeep,S.,Arya, P.,Pooja, T. Antistress activity 
of  Boerhaavia diffusa Root Extract and a polyherbal formulation containing Boerhaavia 
diffusa using cold Restraint stress Model International Journal of Pharmacy and 
Pharmaceutical sciences., 2011,3(1). 
79. Surendra,K., Pareta,Kartik, C.,Patra Ranjeet Harwansh, Manoj Kumar, Kedar Prasad 
Meena. Protective Effects of Boerhaavia diffusa against Acetaminophen-Induced 
Nephrotoxicity in Rats. Pharmcologyonline ., 2011,698-706. 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 82 
 
80. Ramchandra, Y.L., Shilali, K., Mansoor Ahmed, Sudeep H.V., Kavitha,B.T., 
Gurumurthy,H., Padmalatha Rai, S.Hepatoprotective properties of Boerhaavia diffusa 
and Aerva Lanata against carbon tetra chloride induced hepatic damage in rats. 
Pharmacologyonline .,2011, 435-441. 
81. Shisode,K.S., Kareppa, B.M. Invitro Antioxidant activity and phytochemical studies of 
Boerhaavia diffusa Linn.Roots. IJPSR.,2011, 2(12): 3171-3176. 
82. Gopal,T.K., Harish, G.,  Chamundeeswari,D.,  Umamaheswara Reddy, C. Invitro 
Antioxidant activity of  roots of Boerrhaavia diffusa Linn . Research Journal of  
Pharmaceutical Biological and chemical sciences., 2010,1(4): 782. 
83. Apurba Sarker Apu., Mahmuda Sultana Liza., Jamaluddin, A.T.M., Amran Howlader., 
Repon  Kumar Saha. Phytochemical screening and invitro bioactivities of the extracts of 
aerial part of  Boerhaavia diffusa Linn .Asian Pacific Journal of Tropical 
Biomedicine.,2012,2(9):673-678. 
84. Shukla Anamika., and Gupta Rakesh Kumar. Effect of the Aqueous Extract of  
Boerhaavia diffusa  Roots and Leaves of  Hypoglycemic as well as Immuno Support 
Activity. International Research Journal of  Biological sciences.,2012, 1(6):62-65. 
85. Suralkar, A.A., Verma, A.K., Kamble, R.D., and Tayade, G.V., Pharmaclological 
Evaluation of Anti-Histaminic activity of  Boerhaavia diffusa. International Journal of  
Advances in  Pharmacy,  Biology and  Chemistry., 2012, 1(4). 
86. Surendra, K.,  Pareta., Kartik Chandra Patra, Papiya Mitra Mazumder, Dinakar Sasmal.  
Boerhaavia diffusa Linn Aqueous Extract as  Curative Agent in  Ethylene Glycol 
induced Urolithiasis. Pharmacologyonline 3.,2010, 112-120. 
87. Mahesh, A.R., Harish Kumar., Ranganath, M.K., and Raviraj Anand Devkar. Detail 
Study on  Boerrhaavia diffusa  Plant for  its  Medicinal Important – A Review. Research 
Journal of Pharmaceutical sciences., 2012 1(1): 28-36. 
88. Meena, A.K.,  Uttam, S., Niranjan, Yadav, A.K.,  Ajit, K.,  Brijendra Singh, Kiran, M.M  
Rao. A Quality Assessment of  Boerhaavia diffusa  Linn. Commonly Known  as  
Purnarnava Plant.  International Journal of  Pharmacognosy  and  Phytochemical 
Reseach., 2010,2(1):25-28. 
89. Babita Agrawl, Sunanda Das, and Archana Pandey. Boerhaavia diffusa  Linn:A Review 
on its  Phytochemical and Pharmacological Profile.   Asian Journal of  Applied 
sciences.,2011, 4(7): 663-684. 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 83 
 
90. Goyal, B.M.,  Bansal, P., Gupta, V., Kumar, S., Singh. R., Maithani, M.  
Pharmacological Potential of Boerhaavia diffusa: An  Overview.  International Journal 
of  Pharmaceutical Sciences  and  Drug Research., 2010, 2(1): 17-22. 
91. Bhavin,A.,  Vyas, Niket, Y., Desai, Paras, K. Patel, Shrikant, V., Joshi, Dinesh, R.,  
Shah. Effect of  Boerhaavia diffusa  in  experimental Prostatic hyperplasia in  rats.  
Indian  Journal  of  Pharmacology., 2013, 45 (3). 
92. Krishna Murti.,Vijay Lambole., Mayank Panchai., Upendra Kumar. Antidiabetic and 
Antihyperlipidemic Activity  of  Roots of  Boerhaavia diffusa On  Streptozotocin 
induced Diabetic Rats. Phamacologyonline ., 2011, 15-21. 
93. Ajmire, P.V., Dr.  Chidambaranathan, N.,  Dewade, D.R,  Narkhede, M.B., Wagh, A.E. 
Effect of  Boerhaavia diffusa  Against  Dimethylnitrosamine induced Liver Cirrhosis. 
International Jouranl of  Pharmacy and  Pharmaceutical Sciences., 2011, 3(5). 
94. Venkatesh, P,  Dinkar, A., senthilkumar, N.  Evaluation of Analgesic and Antipyretic 
activity of  Alcoholic Extracts of  Boerhaavia diffusa and Anisochilus Carnosus. 
Journal of Current Pharmaceutical Research.,2012,10(1): 15-19. 
95. Mohammad Khalid., Siddiqui, H.H., and Sheeba Freed.Pharmacognostical Evaluation 
and Qualitative Analysis of    Boerhaavia diffusa L. Roots.  International Journal of 
Pharma and Bio Sciences., 2012, 3(1). 
96. Venkatesh, P., Dinakar, A., Senthilkumar, N. Hepatoprotective Activity of  Alcoholic 
Extracts of Boerhaavia diffusa  and  Anisochlilus Carnosus Against Carbon 
Tetrachloride induced Hepatotoxicity in Rats. Asian Journal of  Pharmaceutical and  
Clinical Research2012, 5(4). 
97. Ayurvedic Pharmacopea of India, Part I,Volume I, Government of India: Ministry of 
Health, Department of Ayush, 126-128. 
98. Heywood, V.H.Flowering Plants of the World. Oxford University Press, London, UK. 
1978, 69–70. 
99. Chopra, G.L. Angiosperms. Systematics and Life Cycle. S. Nagin & Co., Jalandhar, 
Punjab, India.,1969, 361–365. 
100. Santhosha D, RameshA, Prasad M Sravan, Kumar Sathis, Kumar Pawan, 
DhanalakshmiCH.Punarnava- A Review. Research Journal of Pharmaceutical, 
Biological and Chemical Sciences .,2011,2 (4): 427. 
101. Ahmed M, Datta BK, Rouf ASS. Phytochemistry .,1990,29: 1709-1710. 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 84 
 
102. Kadota S, Lami N, Tezuka Y, Kikuchi T. Chemical and Pharmaceutical Bulletin .,1989, 
37: 3214-3220. 
103. Lami N, Kadota S, Tezuka Y, Kikuchi T. Chemical and Pharmaceutical Bulletin .,1990, 
38: 1558-1562. 
104. Lami N, Kadota S, Kikuchi T. Chemical and Pharmaceutical Bulletin .,1991,39: 1863-
1865 
105. Jain GK, Khanna NM. Indian Journal of Chemistry., 1989,28(B): 163-166. 
106. Seth RK, Khanna M, Chaudhary M, Singh S, Sarin JPS. Indian Drugs .,1986, 23: 583-
584 
107. Indian Journal of Chemistry .,1984,23(B): 682-684 
108. Lami N, Kadota S, Kikuchi T, Momose Y. Chemical and Pharmaceutical Bulletin., 
1991, 39: 1551-1555. 
 
109. Aslam M. Asian Medicine and its practice in Britain. In: Evans, W.C. (Ed.), 
Pharmacognosy. Saunders Company Ltd, London.,1996, pp. 499–500. 
110. Chanda, B.K., Sharma A.K., Anand, K.K.J. Ethnopharmacol.,1991,31: 299-307. 
111. Rawat A.K.S., Mehrotra S.S., Tripathi C., Shome U. Indian Ethnomedicine .,1997,56: 
61-66. 
112. Adesina S.K. Quarterly J. Crude Drug Research 1979; 17: 84-86. Anonymous. The 
wealth of India Raw Materials CSIRPublication. New Delhi. India. 1988; 174. 
113. Dhanansayan,S., Mark,R.B., Hashim,E.O.,Christian,G.K., Jess,E.R., John,D.F. Grape 
seed and grape skin extracts elicit a greater antiplatelet effect when used in combination 
than when used individually in dogs and humans. The journal of 
nutrition, 2005;135: 172-178 
114. Tamaro, S.H., Diane, K.H., Stephen, D.H., Nomeli,P.N., et al. Inhibition of prostate 
cancer growth by muscadine grape skin extract and resveratrol through distinct 
mechanisms.  The journal of cancer research, 2007; 67(17):8396–405 
115. Revilla , I.,Perez-Manarino,S., Gonzalez-Sanjose,M.L., Identification of anthocyanin 
derivatives in grape skin extracts and red wines by liquid chromatography with diode 
array and mass spectrometric detection.  Journal of chromatography, 1999; 847(1-2): 
83-90 
116. Soares De Moura, R., Costa Viana, F.S., Souza, M.A.V., et al.  Antihypertensive, 
vasodilator and antioxidant effects of a vinifera grape skin extract. Journal of pharmacy 
and pharmacology, 2002; 54(11):1515-20 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 85 
 
117. Andrea, F.E., Emerson, F.Q.. Daniele, D.C.M., Gilson, T.B. Metabolic disorders and 
oxidative stress in adult offspring of rats fed with a high-fat diet (HF) during lactation: 
effects of vinifera grape skin. Journal of cardio vasc pharmacol., 2011;58(3):319-28 
118. Karla, M.P.P., Samuel,S.V., Angela,C.R., Emerson, F.Q.  The preventive effect of grape 
skin extract on pulmonary oxidative response in mice exposed to cigarette smoke. Med 
sci monit,2011;17(8):187-195 
119. Robert Soares, Emerson, F.G., Giselle,F., Michelle, T.T.  Vitis vinifera l. Grape skin 
extract activates the insulin –signalling cascade and reduces hyperglycemia in alloxan 
induced diabetic mice. Journal of pharma. Pharmacol., 2010;64(2):268-76. 
120. Chantal,B., Sylvie,L., Me´Lanie, B., Dominique, B., Denis, G., Richard, B. Inhibition of 
sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial 
cell chemotaxis by red grape skin polyphenols correlates with a decrease in early 
platelet-activating factor synthesis. Free Radical Biology & Medicine,2006; 40:  581–
590 
121. Gonzalo,E., Verónica, S., Marlene, R., Katherina, F. Inhibition of the angiotensin-
converting enzyme by grape seed and skin proanthocyanidins extracted from Vitis 
vinífera L. cv. País. LWT - Food Science and Technology, 2011; 44:860-865 
122. Yoo ,S. J., Joo, H.H, Kyung, H. C., Hee, K. J. Grape skin extract reduces adipogenesis- 
and lipogenesis-related gene expression in 3T3-L1 adipocytes through the peroxisome 
proliferator-activated receptor-γ signaling pathway. N u t r i t i o n Re s e a r c h, 2 0 1 2; 
3 2: 5 1 4 – 5 2 1 
123. Lei ,Z, Shelly H, Jianrong L B, Shi S D, Corene C D, Shao J, Kequan Z. Grape skin 
extract inhibits mammalian intestinal α-glucosidase activity and suppresses postprandial 
glycemic response in streptozocin-treated mice. Food Chemistry, 2011; 126: 466–471 
124. Alaa El-Din, A. B, Vern J.C, Michelle, M, Jenny H.Z, Richard,S. Antioxidant activities, 
sensory and anti-influenza activity of grape skin tea infusion. Food Chemistry, 
2011;129: 837–845 
125. Sonia,H, Oumayma,S, Meherzia,M, Nadia,L. Protective effect of grape seed and skin 
extract on high dosage garlic-induced renal oxidative stress. Bangladesh J Pharmacol 
2012; 7: 77-86 
126. Seong-Mo, K, Sang-Chan, K, In-Kwon, C,etal. Antioxidant and Protective Effects of 
Bupleurum falcatum on the l-Thyroxine-Induced Hyperthyroidism in Rats. Evidence-
Based Complementary and Alternative Medicine,2011 :pg 1-12 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 86 
 
127. Vasundhara,S, Dharamveer, Rajiv, G, Shubhini,A., Saraf. Ficus Carica Leaf Extract In 
Regulation Of Thyroidism Using Elisa Technique. Asian Journal of Pharmaceutical and 
Clinical Research, 2012;5(2):44-48 
128. Amar, K.C., Sabyasachi, S., Shyamosree, R.C.The thyroxine induced stress and its 
possible prevention by catechin in rats. Indian journal of experimental biology, 
2010;48:559-565 
129. IBRAHIM, A.K., Effects of resveratrol on thyroid function in normal and hyperthyroid 
rats.  department of pharmacology ,college of pharmacy,king saud university. 
130. Idris, M.A.., Idris,O.F., Sabahelkhier,M.K. The effects of induced hyperthyroidism on 
plasma fsh and lh concentrations in female of wistar rats. Research Journal of Recent 
Sciences,2012; 1(6),:55-57 
131. Tahani ,S. S., Reverse effect of laser treatment on hyperthyroidism in female rabbits. 
Kufa Journal For Veterinary Medical Sciences, 2011;2(1): 30-38 
132. Thoudam, B., Ramya,J., Usha,K. Effect of methanolic extract of sweet corn silk on l 
thyroxine induced hyperthyroidism in swiss albino rats. International research journal of 
pharmacy,2012;3(3):241-245 
133. Dehghani, F., Panjehshahin, M. R., Vojdani, Z.  The Effect of hydroalcoholic extract of 
caraway on thyroid gland structure and hormones in female rat. Iranian Journal of 
Veterinary Research, Shiraz University, 2010; 11(4): 337-341 
134. SUNANDA ,P.,ANAND, K. studied the anti-thyroid action of leaf extract of Annona 
squamosa in albino rats. CURRENT SCIENCE2003;84(11):1402-1404 
135. Kar,A., Panda,S.,Bharti,S. The Relative efficacy of three medicinal plant extracts in the 
alteration of thyroid hormone concentrations in male mice. Journal of 
Ethnopharmacology,2002; 81:281-285 
136. Panda,S., Jafri,M.,  Kar,A., Meheta, B.K.  The Thyroid inhibitory, antiperoxidative and 
hypoglycemic effects of stigmasterol isolated from Butea monosperma. Fitoterapia, 
2009; 80:123-126 
137. Jean-Marc, S., Franck,B., Michel,M.  The Polymeric proanthocyanidins from grape 
skins. Phytochemistry,1996;43(2):509-512 
138. Margarita, C., Avelina, F., Et Al. Extraction of anthocyanins from grape skins assisted 
by high hydrostatic pressure.  Journal of food engineering, 2009;90(4):415-421. 
 
Arulmigu Kalasalingam College of Pharmacy 
Department of pharmacology Page 87 
 
139. Laura,L., Monica,M., Marta,R., Rosa,S.,  et al. Toxicology evaluation of a procyanidin-
rich extract from grape skins and seeds. Food and chemical toxicology, 2011; 
49(6):1450-1454 
140. Rosalia Rodriguez,R., Maria ,L.J, Carmen, M.C, Elisabet ,V., et al . Endothelium-
dependent vasodilator and antioxidant properties of a novel enzymatic extract of grape 
pomace from wine industrial waste. Food chemistry, 2012;135: 1044–1051 
141. Sun, T., Chen, Q.Y., Wu,L.J., Yao, X.M., Sun,X.J. Antitumor and antimetastatic 
activities of grape skin polyphenols in a murine model of breast cancer. Food and 
chemical toxicology,2012;50(10):3462-67 
142. Sunanda, P, Anand ,K, Shridhar, P. Soy sterols in the regulation of thyroid functions, 
glucose homeostasis and hepatic lipid peroxidation in mice. Food Research 
International, 2009;42: 1087–1092 
143. Sunanda,P, Pankaj,.,  Anand, K. How safe is neem extract with respect to thyroid 
function in male mice. Pharmacological Research, 2000;41(4):420-22 
144. Sunanda,P, Pankaj,.,  Anand, K. Inhibition of triiodothyronine production by fenugreek 
seed extract in mice and rats. Pharmacological Research,1999;40(5):406-409 
 
 
 
 
 
 
 
